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Abstract
This thesis aim is to purpose the design of an automatic close-loop
control system for general anaesthesia. General anaesthesia is achieved
through the administration of pharmaceutical drugs, which produce
an effect on patients undergoing surgery.
To achieve the aim of this research clinical data obtained from a set-
up assembled at King’s College Hospital and used for estimation and
optimization of Pharmacodynamic (PD) models associating effect-site
concentrations of propofol, remifentanil and cardiac output to BIS
readings. These models were estimated using two techniques, Hill
equation and support vector regressors (SVRs) based models. The
use of SVRs as a modelling technique allows the incorporation of
additional biological signals The SVR technique may produce a non-
parametric model which does not guarantee total adequacy of the
estimated model as a PD model, therefore a Model Adequacy Index
was proposed to assess compliance of the estimated models based on
the expected clinical behaviour.
PD models considering both pharmaceutical drugs estimated through
the SVR technique and Gaussian radial basis kernel presents a con-
siderably higher performance when compared to the estimated multi-
drug Hill model.
iii
Three proportional-integral-differential (PID) controllers are employed,
namely linear PID controller, type-1 (T1) fuzzy PID controller and
interval type-2 (IT2) fuzzy PID controller, to regulate the bispectral
index using the nominal patient’s model. The PID gains and mem-
bership functions are obtained using genetic algorithm (GA) by min-
imizing a cost function measuring the control performance. The best
trained PID controllers are tested under different scenarios and com-
pared in terms of control performance. Simulation results show that
the IT2 fuzzy PID controller offers the best control strategy regulating
the BIS index while the T1 fuzzy PID controller comes second.
iv
Statement of contributions
According to the knowledge of the author, this thesis has the following
contributions which are asserted to be original.
• Setup of clinical platform for synchronized clinical data at King’s
College Hospital, presented on Chapter 2. Clinical data has been
recorded for a high number patients undergoing surgery and 42
of these cases was used in this thesis.
• Development of pharmacodynamic models using support vector
regression techniques with the consideration of different kernel
functions reported in Chapter 3.
• Application of non-parametric modelling technique to the phar-
macodynamic modelling allowing the incorporation of additional
variables. Pharmacodynamic model incorporation nominal car-
diac output performance is reported in Chapter 3.
• Development of an index assessing the validity and adequacy of a
SVR-based model as pharmacodynamic model based on clinical
knowledge is discussed in Chapter 3.
• Design and testing of controllers for BIS index regulation includ-
ing traditional PID controller, type-1 fuzzy PID controller and
v
interval type-2 fuzzy PID controller for administration of propo-
fol and remifentanil based on estimated PK/PD models. These
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Anaesthesiologists provide an adequate general anaesthesia by continuously as-
sessing and judging the state of patients based on various observations. Anaes-
thesia commonly depends on a combination of various drugs which presents a
variety of interactions. Additionally patients’ intra and inter-individual variabil-
ity is also present as all these processes take place on a complex biological system,
the human body, often throughout several hours. Due to all these characteristics,
anaesthesiology is a complex control task which would benefit from an automatic
control system which automatically adjusted the amounts of drugs infused to
achieve a desired clinical effect. A reliable and robust patient model is required
to design and develop such a system. Such a model would also prove beneficial for





The first public demonstration of general anaesthesia during surgery can be traced
back to 16 October 1846; ether anaesthesia administrated by William T. G.
Morton in the Massachusetts General Hospital in Boston [44]. After this event
the word anaesthesia, which is derived from Greek for without-perception, was
suggested to describe the effect observed. Ether anaesthesia was rapidly adopted
around the world, having been successfully administrated in London two months
following Morton’s public demonstration. This event is widely considered the
starting point of the anaesthesiology speciality.
1.1.1 Defining general anaesthesia
General anaesthesia is a reversible state where patients undergoing surgery are
temporarily deprived of consciousness with the purpose of undergoing an op-
eration without pain and creating good operating conditions for the surgeon.
General anaesthesia is defined by three main components: unconsciousness, anal-
gesia and muscle relaxation, which is conveyed through various behavioural effects
such as amnesia, hypnosis, analgesia, immobility and dimmed automatic reflexes.
Additionally homoeostasis and prevention of injuries are achieved through phar-
macological manipulation of major organ systems. The clinical aim of general
anaesthesia is to achieve an adequate mix of various drugs concentrations to pro-
duce the desired clinical effect while remaining below unsatisfactory toxicity levels
[44].
Unconsciousness in general anaesthesia, also mentioned as hypnotic compo-
nent of general anaesthesia, consists of a person being unaware, i.e. not having
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perception, of himself/herself and unable to receive and process external infor-
mation. Patients under general anaesthesia are expected to be in a state of
unrousable unconsciousness, i.e. unable to be awoken despite applied stimulus.
The depth of anesthesia (DOA) represents the level of consciousness [48]. Aware-
ness during general anaesthesia, which consists of patients’ consciousness during
intra-operative events and following explicit recall, is a clinical complication that
may have a serious impact on patients who experience it, such as post-traumatic
stress disorder.
Analgesia, i.e. pain relief, is widely achieved during general anaesthesia through
use of opioid drugs as they are able to block nociceptive information resulting from
several noxious stimulus, such as skin incision, which patients are subjected to
during surgical procedures. In the absence of an adequate analgesia component,
the various noxious stimulus will prompt an undesired patients’ nociceptive re-
sponse. Additionally, the use of opioid in general anaesthesia can reduce somatic
and autonomic responses.
Additional muscle relaxation is commonly achieved during general anaesthe-
sia via administration of neuromuscular blockers ensuring patients paralysis. Pa-
tients’ immobility needs are dependent on surgical procedures which should be
taken into account in the administration of neuromuscular blockers in order to
minimize its cardiovascular and respiratory side effects. Neuromuscular block-
ers are a value auxiliary drug in general anaesthesia however as neuromuscular
blockers do not present amnesic nor analgesic properties there is a high risk of
awareness during surgery with possible serious psychological consequences for the
patients. In order to minimize this risk, depth of anaesthesia and level of analge-
sia should be continuously monitored and ensured. Muscle relaxation facilitate
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tracheal intubation and provides optimal conditions for the surgeon having a
important impact on the development of various surgeries.
Even through a single drug can be used to achieve general anaesthesia sat-
isfying the three components, it may require doses which produce high haemo-
dynamic depression. A balanced anaesthesia is the common practice where a
combination of different drugs is used to provide the required levels for each of
the anaesthetic components, such as an opioid and a neuromuscular blocker for
the analgesia and muscle relaxation components respectively. However the use of
a balanced anaesthesia introduces a drug interactions problem where the effect
of a certain drug might be modified by the presence of another drug, amplifying
or reducing its effect.
General anaesthesia is usually divided into three phases: induction, mainte-
nance and recovery [16]. Induction is the first phase of anaesthesia where the aim
is to produce an unrousable unconsciousness state in the patient in preparation
to the surgical procedure. Maintenance phase follows induction and it is during
this phase that the surgical procedure takes place. The last phase is recovery
where a safe and comfortable return of consciousness is expected following the
surgery.
A combination of pharmaceutical drugs of different classes, such as hypnotic,
opioid and neuromuscular blockers, is used by anaesthesiologists to induce gen-
eral anaesthesia during surgery with the aim of producing a balanced anaesthesia.
Each administrated drug has an expected clinical effect due to its interactions
with the patient under surgery. These interactions can be divided into pharma-
cokinetics (PK), the relation between the administrated dose and its concentra-
tion, and pharmacodynamics (PD), the relation between its concentration and
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the clinical effect [1].
During induction a combined dose of pharmaceutical drugs high enough to
obtain an unrousable unconsciousness state and achieve safe and comfortable
conditions to perform endotracheal intubation or laryngeal mask airway insertion
should be administrated to the patient. Induction is a critical phase of general
anaesthesia where profound changes to patients’ central nervous, respiratory and
cardiovascular systems may occur and as such needs to be closely monitored and
administration of the various pharmaceutical drugs performed in accordance with
their evolution. Severe respiratory depression occurs during anaesthesia induction
which creates the need for mechanical ventilation. Cardiovascular depression is
also a common occurrence if no steps are taken to avoid it.
Following induction of anaesthesia, the anaesthesiologist maintains an ade-
quate anaesthesia for the surgical procedure managing the levels of hypnotic,
analgesic and muscle relaxation components while ensuring patient’s overall ho-
moeostasis though administration of various drugs, intravenous infusion of fluid
or blood as required to maintain and manipulate haemodynamic stability and
essential functions of major organ systems. Depending on the surgical procedure,
this phase of anaesthesia may last several hours throughout which the anaesthe-
siologist’s strategy might need to change and adapt to changes in the patient’s
condition.
Recovery is the last phase of general anaesthesia at the end of surgical pro-
cedure where the aim is a safe and comfortable return to consciousness and to
normal bodily functions, such as spontaneous ventilation and reversal of muscle
relaxation. Titration of hypnotic and neuromuscular blocker are stopped, how-
ever analgesia is still maintained in order to cope with the pain arising from the
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performed surgical procedure. Depending on the surgical procedure recovery may
occur in the operating theatre just after the end of surgery or hours later in a
recovery unit. Various drugs are available to facilitate and reduce recovery time
[5].
1.1.2 Propofol, Remifentanil and their effect
As mentioned in the previous section, a balanced anaesthesia is the standard
practice for general anaesthesia. This entails the administration of various phar-
maceutical drugs via inhalation or intravenous infusion or a combination both.
Inhalational anaesthesia has been used since the mid-19th century with, for in-
stance, nitrous oxide, isoflurane, and halothane as commonly used drugs [47].
Total intravenous anaesthesia (TIVA) is the practise of induction and mainte-
nance of general anaesthesia solely recurring pharmaceutical drugs administrated
to the patient through intravenous infusion with the following advantages[27]:
provision of anesthesia separate from ventilation, reduced atmospheric pollution,
rapid and clear-headed recovery, and so on. While inhalational anaesthesia is still
frequently used, intravenous anaesthesia has become increasingly popular due to
the rapid and safe transition [62].
Propofol, a drug with hypnotic properties, is the most commonly used in-
travenous anaesthetic drug today with the aim of providing the unconsciousness
component of general anaesthesia. During TIVA the analgesic component is pro-
vided by the intravenous infusion of an opioid in addition to propofol, commonly
remifentanil [33].
As previously mentioned, co-administration of more than one drug may pro-
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duce additive, synergistic or infra-additive interactions producing a distinct clini-
cal effect for the drugs combination. Mathematical models representing the drugs’
joint pharmacodynamics can be used to describe these pharmacological interac-
tions [46]. These interactions can also potentiate the side-effects of anaesthetic
drugs, such as a decrease in the patient’s haemodynamic parameters. Propofol
and remifentanil have a synergistic interaction when jointly administrated.
The effect of the anaesthetic drugs on the central nervous system can be
obtained by analysing the electroencephalogram (EEG) with measurements such
as Bispectral Index (BIS) which is a processed EEG parameter calculated with the
BIS algorithm [31]. Using time domain, frequency domain and bispectral analysis,
the BIS algorithm combines various EEG features, which are highly correlated
with hypnosis in the EEGs from more than 5000 adults subjects, to provide a
reliable parameter for anaesthetic hypnosis. BIS index is a dimensionless number
between 0 and 100 which correlates with the clinical state of the patient and is
a good indicator of the the patient’s cortical surpression [2, 31, 39]. There are
several monitors such as BIS, all based in the EEG and using different signal
processing techniques, but it is worth mentioning that they do not fully describe
the state of conscious or unconsciouness, they are representative of the effect of
the drugs on the EEG, which is in turn is used to assess the brain’s activity.
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1.2 Modelling and control for drug administra-
tion
The study of drug interactions is of major importance as it can provide guidelines
to optimize drug administration during general anaesthesia and therefore reduces
the amount of drug necessary and its recovery time. Modelling the effects of
anaesthetic drugs would also enable anaesthetists to access simulation training
through Human Patient Simulators which incorporated PK and PD models. Ad-
ditionally, a better understanding of the anaesthetic drugs interactions and their
effects on patients would provide useful information for the design of an auto-
matic controller system for induction and maintenance of general anaesthesia,
potentiating further improvements in patient safety.
Using population pharmacodynamic analysis, PD models [10, 21, 46, 61] for
anaesthetic drugs have been estimated, but due to inter and intra-individual vari-
ability and the change in conditions caused by surgery, these may not reflect the
most accurate assessment of the state of patient. During surgery, various surgical
stimulus and perturbations, such as incision and blood loss, can occur which may
have an impact on the drugs’ potency and interaction power. These PD models
are based on a defined sigmoid curve and cannot contemplate the surgical stim-
ulus and perturbations nor other variables which may impact upon them. The
incorporation of other factors and techniques may therefore be advisable.
The main difficulties involved in modelling are the determination of PD model
parameters and the selection of the output index. In general, the parameters of
PK and PD models need to be determined beforehand. For the PK model,
parameters can be estimated depending on the sex, age, and weight of patients.
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Nonetheless, for the PD model, it is not possible to estimate the parameters for
certain patient. Accordingly, it requires the controller to be robust in a domain
of PD model parameters [23]. Although PK model parameters are varied with
patients and PD model parameters can change for just one patient, a general
index can be designed to evaluate the DOA for all patients [34].
In general, control strategies can be categorized into two classes: open-loop
control and closed-loop control. In the anaesthetic field, open-loop control is
based on the knowledge and experience of anaesthetists who manually adjust the
drug dosage to maintain the DOA assisted by some clinical indices of patients.
In closed-loop control, the drug dosage is automatically adjusted according to
some indices of DOA, which makes control input continuous and responsive [51].
Closed-loop control is also expected to avoid over- and under-dosage and suppress
the adverse effect of inter-individual differences [32]. Despite its advantages, the
stability of closed-loop control needs to be ensured due to the automated process
without supervision [58].
To achieve the stabilization based on closed-loop control, the following compo-
nents are required [59]: (1) a patient model, with an output as the index of DOA;
(2) a controller for stabilization, such as proportional-integral-differential (PID)
controllers. Therefore, to begin with, an estimated patient model is required to
represent real patients supporting the control design and performance evaluation.
A widely employed mathematical model consists of a linear PK model and a non-
linear PD model [8]. The PK model uses the drug dosage as the input and the
drug concentration as the output. In what follows, the PD model exploits the
drug concentration as the input and exports the index of DOA.
With regard to the controllers for stabilization, several control problems are
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faced with the closed-loop control of anesthesia: stability, which is the basic con-
trol objective; robustness, which overcomes the uncertainty of PD model param-
eters, measurement noise, surgical stimulation, and so forth; adaptiveness, which
makes the controller adaptable to different patients rather than only one patient.
Commonly used controllers include PID controllers, model-based controllers, and
knowledge-based controllers [59].
To close the loop of control systems, the classical PID controller is undoubt-
edly option due to its successful applications in other areas. For stabilization,
it is necessary to tune the parameters of PID controllers for a certain patient
model. While the tuning process is an empirical manner, some tuning schemes
have been developed to guarantee the robustness [19, 52]. Combined with patient
model identification from the induction phase of anesthesia [57], the adaptiveness
can be further achieved. In addition, combined with genetic algorithm (GA), the
parameters of PID controllers can also be online optimized [55].
Despite various causes of the changes in PK and PD model parameters, the
model-based controller relies on the current model which reflects the patient’s
current pharmacological behavior. For this reason, the patient model needs to be
updated through the overall process of anesthesia. This online adaptation can be
achieved by several approaches such as Kalman filter algorithm [53], Bayesian-
based adaptive control [17], and adaptive genetic fuzzy clustering algorithm [55].
Alternatively, the variability of PK and PD models between individuals as well as
surgical stimulation and anesthetic-analgesic interaction can be explicitly consid-
ered oﬄine such that the stability is mathematically guaranteed [26]. Addition-




Unlike model-based controllers, knowledge-based controllers do not require a
known mathematical model. In fuzzy logic controllers, for example, decisions are
made based on fuzzy rules predefined by expert knowledge and experience. Com-
pared with linear PID controllers and model-based controllers, knowledge-based
controllers are easier to implement without tuning PID parameters or mathe-
matical derivation. A hybrid control scheme, namely fuzzy-PID control, was
developed to combine the merits of both control strategies [3]. Moreover, a mul-
tivariable neural-fuzzy controller was proposed to simultaneously administrate
both propofol and remifentanil [40]. However, one problem of knowledge-based
controllers is that the interaction of each piece of knowledge makes the controller
less transparent and makes it difficult to achieve adaptive control [59]. To deal
with this problem, a direct adaptive interval type-2 (IT2) fuzzy logic controller
was proposed for multivariable anesthesia systems [20] and a genetic fuzzy logic
controller was developed to adjust fuzzy rules using GA [55].
1.3 Project aims and objectives
This project aims to design a close-loop control system for general anaesthesia.
To achieve this aim two objective were establish. A robust and reliable PK/PD
model describing anaesthetic drugs interactions, namely hypnotic propofol and
analgesic remifentanil using real clinical data from patients needs to be developed
and to design a controller to administrate the drugs automatically to regulate the
BIS index. To realize the project aim and objectives, the following step have been
considered.
• Set up a clinical platform consisting of laptop running a data synchroniza-
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tion and recording software developed by our research team, connected to
various medical devices including Alaris PK infusion pumps, BIS Vista
monitor, LiDCOrapid monitor and INVOS monitor.
• Collect patients’ data for investigation. The data include BIS, propofol
and remifentanil infusion rates and predicted concentration, brain regional
oxygen saturation (rSO2) and various haemodynamic parameters such as
heart rate, blood pressures, nominal cardiac ouput (nCO) and stroke volume
(SV).
• Determine the parameters of Hill’s PD model using patient’s data for com-
parison purposes. Genetic algorithm using different cost functions and least
squares methods fitting were employed.
• Develop a more accurate PK/PD model using support vector regression
techniques with the consideration of different kernel functions.
• Design an evaluation function to measure the modelling performance and
validity of the developed support vector regressors (SVR)-based models.
• Based on the PK/PD model with the patient’s parameters, control method-
ologies are designed to administrate the drugs for the regulation of BIS in-
dex. Various controllers including traditional PID controller, type-1 fuzzy
PID controller and interval type-2 fuzzy PID controller are considered.




• Apply genetic algorithm to determine the controller gains by optimizing the
fitness function.
To summarize, the PK/PD model is employed to describe the dynamics of
patient’s body responding to the hypnotic propofol and analgesic remifentanil.
By investigating the closed-loop system formed by the PK/PD model and a con-
troller, a control methodology is proposed to administrate the drugs controlling
its inflow to the patient’s body such that BIS index regulation can be regulated.
1.4 Thesis structure
This thesis is divided into five chapters, one appendix and references. A brief
explanation of the contents of each chapter is presented below.
Chapter 2 discuss the set up implemented at King’s College Hospital for data
collection, a description of the clinical protocol followed by the anaesthesiologist
to induce general anaesthesia. Technical details for published PK/PD models are
also explained in the chapters with the description of PK models implementation
in MATLAB for the porpuse of simulation for support of this project.
Chapter 3 introduces the estimation of PD models from clinical data. Two
approaches are studied in this thesis, a parametric technique based on the Hill
equation and a non-parametric one based on the use of SVRs. Using SVRs to
develop a PD model enables the incorporation of additional biological variables
into the PD model. However adequacy of the estimated models needs to be
assessed, and a index is described in order to measure adequacy.
In chapter 4, various proposed control methodologies such as, linear PID con-
troller, type-1 (T1) fuzzy PID controller and interval type-2 (IT2) fuzzy PID
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controller, are discussed and the results obtained in simulation environment sup-
ported by estimated PD model on the previous chapter are presented.
The final chapter presents the conclusion of the research and sets recommen-
dations for future work.
In the appendix an initial continuous in time simulink implementation of the






Administration of an adequate general anaesthesia is a complex art that requires
the anaesthesiologist to continuously analyse and make judgements about the
state of the patient based upon a variety of observations, clinical monitors and
drugs administrated to the patient. A system allowing continuous collection of
clinical data observed by the anaesthesiologist is therefore an invaluable tool for
this research project.
2.2 Clinical Protocol
Before induction of anaesthesia, intravenous access with a plastic cannula is ob-
tained. Various anaesthetic drugs and fluids are administrated through it during
15
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the surgery. Standard anaesthetic monitoring is also initiated pre-induction which
includes pulse oximeter, non invasive blood pressure (NIBP), electrocardiograph
(ECG), airway gases and pressure. In addition to standard anaesthetic moni-
toring, right cerebral regional oxygen saturation, BIS index and various haemo-
dynamic parameters obtained from LiDCOrapid monitor (LiDCO PLC, London,
UK) are also monitored pre-induction. Details of non-standard anaesthetic mon-
itoring is discussed on Section 2.3.
Patients receive TIVA with propofol and remifentanil target controlled infu-
sion (TCI) by two Alaris R© PK infusion pumps using Marsh [41] and Minto [45]
PK models respectively. For details of TCI refer to Section 2.4.1.2.
Induction starts with a remifentanil plasmatic concentration (Cpremi) target
of 3 ng/ml. When remifentanil effect-site concentration (Ceremi) of 2 ng/ml is
reached, Cpremi target is adjusted to 2 ng/ml and propofol infusion is started
with a propofol plasmatic concentration (Cpprop) target of 3 µg/ml and adjusted
therefore according to BIS index readings in order to BIS reach the interval 40
to 60. Loss of consciousness (LOC), i.e. the patient stops responding to verbal
commands and mechanical stimulus, is expected to have happened by this point.
A neuromuscular blocker, usually cisatracurium, is also simultaneously manually
infused.
Once BIS index below or around value 50 is achieved for a period of 2 minutes,
laryngeal mask airway insertion takes place. Therefore, propofol and remifentanil
plasma concentration targets are manually adjusted by the anaesthetist during
surgery according to readings of the various clinical monitoring equipments, the
expected effect of administrated anaesthetic drugs and noxious stimulus expected
to take place in order to provide an adequate general anaesthesia.
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Throughout surgery additional drugs or fluids are administrated to maintain
homoeostasis according to the judgement of the anaesthesiologist. For example,
nCO is monitored during all stages of surgery, and the anaesthetist takes the nec-
essary steps, such as performing a fluid challenge which involves a rapid infusion
of 250 ml of colloid fluid to ensure the nCO is maintained at a stable condition
at or near pre-induction level.
Once the end of surgery is approaching, additional analgesic drugs are admin-
istrated to the patient to ensure analgesia is present when the patient recovers
consciousness to cope with the pain arising from the surgical wound. These de-
pend on the degree of pain anticipated from the surgery and might be intravenous
paracetamol or morphine, for example.
Once the state of general anaesthesia is no longer necessary, the infusion of
propofol and remifentanil are stopped and the anaesthesiologist ensures that a
smooth, safe and comfortable recovery takes place.
2.3 Setup at King’s College Hospital
One of the essential components of this project is recording data from the patient
immediately before, during and immediately after the administration of general
anaesthesia in the operating theatre. The analysis of collected data will enable
the extraction of information showing signals that are relevant to establish the
state of the patient. The data recorded during surgery is also indispensable to
develop and establish accurate and robust PK/PD models and assist with the
design and simulation of an automatic controller.
To achieve this target, a system (Figure 2.1) was assembled at King’s Col-
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lege Hospital comprising of a laptop connected to various medical devices for
continuous data collection during the entire duration of general anaesthesia.
Figure 2.1: Data recording set-up system at King’s College Hospital operating
theatre.
ASYS (Anesthesia Synchronization Software) [9] (Figure 2.2), a data acquisi-
tion software developed by our research team, runs on the laptop recording the
values it receives from various medical devices it is connected to every 5 seconds,
two Alaris PK infusion pumps, BIS Vista monitor, LiDCOrapid monitor and
INVOS monitor (Figure 2.3). None of these devices is controlled or its behaviour
is in any way affected by ASYS as it only records the data provided by these
18
2. ANAESTHESIA PROTOCOL AND CLINICAL SETUP
devices and the anaesthetist has complete access and control over all monitoring
equipment.
Figure 2.2: Data record software ASYS.
The Alaris PK infusion pumps are the devices which regulate the infusion
of anaesthetic drugs propofol and remifentanil with the built-in TCI algorithm.
From the infusion pumps, ASYS records the current plasma target concentration
(Cpt) defined by the anaesthetist, the current plasma concentration and effect-
site concentration estimated by the pump PK model, the current infusion rate
and the amount of drugs administrated since the beginning of infusion.
BIS Vista monitor provides BIS index which is a processed EEG parameter
calculated by BIS algorithm. Using time domain, frequency domain and bispec-
tral analysis, the BIS algorithm combines various EEG features which are highly
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Figure 2.3: Medical devices that comprise setup for data recording at King’s
College Hospital. Alaris PK infusion pump (left upper image) [11]. BIS Vista
monitoring system (left bottom image) [15]. LiDCOrapid monitor (right upper
image) [38]. INVOS monitor (right bottom image)[14].
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correlated with hypnosis in the EEGs from more than 5000 adults subjects. The
BIS index is a dimensionless number between 0 and 100 which correlates with the
clinical state of the patient and is a good indicator of patients’ unconsciousness
(Figure 2.4) [2, 31]. ASYS records the BIS index, electromyography (EMG) and
suppression ratio (SR) of EEG from this device.
Figure 2.4: BIS range guidelines [31].
LiDCOrapid monitors patient’s fluid and hemodynamic status by analyzing
and processing the continuous arterial pressure waveform obtained from an radial
arterial line placed pre-induction. Patient’s fluid and hemodynamic status is
showed by various cardio-vascular parameters, such as heart rate (HR), systolic
(SYS), mean (MAP) and diastolic (DIA) blood pressure, SV, nCO, pulse pressure
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variation (PPV) and stroke volume variation (SVV). All these cardio-vascular
parameters are recorded with ASYS throughout surgery including pre-induction
baselines.
INVOS is a regional oxymetry monitor which provides the regional blood
oxygen saturation (varies between 0 and 100%) in cerebral and somatic tissue.
The measurement follows a non-invasive method where a sensor is placed in the
patient. For this research project right-side oxygen saturation (rSO2) is assessed
on the right side of the brain as the brain is susceptible to oxygen deprivation.
rSO2 provides tangible information about cerebral perfusion which can be used in
conjunction with other variables to avoid cerebral ischemia. Only the saturation
value is recorded by ASYS. Pre-induction INVOS and BIS 4 electrode sensors
are attached to the right and left sides of the patient’s forehead, respectevely, to
obtain baseline readings on all clinical monitors.
During the installation and configuration of the system, the anaesthetist Dr
David Green made some suggestions and gave advice on which features would be
useful to include in the system. A close contact was maintained with the ASYS
developer to adjust these features throughout this research project.
Data records are compiled of patients undergoing surgery under general anaes-
thesia administrated by Dr David Green. Usually, data are collected every week
with my presence in the operating theatre from one or two patients undergoing
vascular surgery. ASYS automatically records the data from the connected de-
vices every five seconds and the laptop user has the responsibility of registering
on ASYS any event which may have any importance on the patients state, like the
start of incision or the administration of other drugs, for example ephedrine. The
data recording process does not interfere in any way with the usual and standard
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practise of the anaesthetist. Local ethical committee approval was sought but
was not deemed necessary as the procedures carried out were normal practice at
King’s College Hospital.
2.4 Pharmacokinetic / Pharmacodynamic Model
- Technical details
2.4.1 Pharmacokinetic Model
The pharmacokinetics of a drug is the relation between the dose administered and
its concentration in the blood. Pharmacokinetics is usually defined as what the
body does to the drug. A PK model is a mathematical model of this relationship,
which describes the process of drug distribution and elimination. It can be used
to predict the blood/plasma concentration and effect-site concentration profile of
a drug after its administration whether by bolus or infusion [1].
The PK models for most of the drugs are multi-compartmental. The one- and
two-compartment models can be used to describe the pharmacokinetics behaviour
of drugs within a large therapeutic window. However for a PK model of the
hypnotic and analgesic drugs administrated intravenously for general anaesthesia,
particularly propofol and remifentanil, a three-compartmental structure is usually
used (Figure 2.5) [22].
Drug metabolism and distribution rates can be expressed by rate constants,
which represent the proportion of drug suffering elimination or distribution during
a unit of time. The drug is infused in the patient at a rate r(t) (mg/min).
By convention the compartment into which the drug is injected is called central
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Compartment











Figure 2.5: Structure of a three-compartmental with effect-site compartment
pharmacokinetic model. r(t) is the infusion rate of the drug, k10, k12, k13, k21,
k31, k1e and ke0 are rate constants for distribution and elimination of the drug.[1]
compartment and its volume, V1 (l), is the initial volume of distribution. There is
a rapid drug re-distribution between the central compartment and compartment
2 defined by the rate constants k12 (min
−1) and k21 (min−1) and a slower drug
distribution between the central compartment and compartment 3 described by
the rate constants k13 (min
−1) and k31 (min−1). The volumes of compartment
2 and 3 are represented by V2 (l) and V3 (l), respectively. The rate constant k10
(min−1) represents the drug elimination from the central compartment [1].
The effect-site compartment is a hypothetical compartment, without volume
by definition, used to describe the delay between the blood/plasma concentra-
tion and the effect-site concentration. Because of the definition of the effect-site
compartment as a volume-less compartment, the rate constants k1e and ke0 are
equal. This subject will be further explained later. The changes in the amount of
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where m1(t) is mass of drug in the central compartment (mg); m2(t) is mass of
drug in the compartment 2 (mg); m3(t) is mass of drug in the compartment 3
(mg); r(t) is infusion rate (mg/min); k10, k12, k13, k21, k31 are rate constants for
the transfer of drug (min−1).
The blood/plasma concentration of the drug can be calculated dividing the
mass of drug in the central compartment by its volume (Cp(t) = (m1(t)/V1). The
volumes of the compartments on the three-compartment model are theoretical
volumes which are used to calculate the blood/plasma concentration of a drug,
and they can not be associated with any anatomical or physiological meaning.
As referred to previously, there is a delay in time between the equilibration of
the effect-site concentration and the blood/plasma concentration, time to peak ef-
fect (TTPE). Factors like cardiac output, cerebral blood flow and pharmacological
properties of the drug influence the rate of equilibration between blood/plasma
and effect-site. The parameter ke0 can describe the delay of the blood and effect-
site equilibration, and the effect-site concentration can be obtained from the
blood/plasma concentration using the following differential equation [50]:
dCe
dt
= ke0Cp(t)− ke0Ce(t), (2.2)
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where Cp(t) is blood/plasma drug concentration (g/ml); Ce(t) is effect-site drug
concentration (g/ml) and ke0 is rate constant.
Since the PK of most anaesthetics appear to be linear, i.e. the shape of drug
concentration decay and the derived pharmacokinetic parameters are unaffected
by the dose, within clinical dosage, the pharmacokinetic parameters can be used
to calculate the blood/plasma concentration generated by any bolus or infusion
scheme [22].
2.4.1.1 Discretization of Pharmacokinetic (PK) models
One of the objective of this research project is to develop a digital controller
and as the devices which it will be controlling work in a discrete time domain,
discretization of the PK model is needed.
From the differential equations which describe the changes in the amount of
drug in each of the three compartments and relate to the plasma concentration
with the effect/site concentration, and converting time from minutes to seconds,
a state space representation for the continuous time PK models, equation (2.3)
can be obtained.
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 1V1 0 0 0
0 0 0 1

ke0 (min
−1) is a parameter describing the delay in time of the plasmatic-effect-site
drug concentration equilibration.
A zero order hold assumption for the PK models, this is, the input signal,
infusion rate, does not experience any alteration during the sampling interval can
be made. Also assuming that uniform sampling intervals, Ts, the state space
representation for the discrete time PK models can be represented by equation
(2.4) [49].
x[n+1] = Ax[n] +Bu[n]












, u[n] = r(nTs),





G = F−1(A− I)G
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2.4.1.2 TCI Target controlled infusion
Using the PK models of the drug, TCI systems calculate the infusion rate neces-
sary to obtain and maintain a desired blood/plasma concentration. The TCI sys-
tems follow an infusion scheme designated as BET (bolus-elimination-transfer).
Initially a bolus is administrated to achieve the blood/plasma target concentra-
tion (Cpt) on the central compartment equation (2.5), following a continuous
infusion with a rate of r(t), to compensate for the loss of the drug by the elimina-
tion process and replace the drug transferred between the central and peripheral
compartments equation (2.6).[4]
LD = V1Cpt (2.5)
r(t) = LD(k10 + k12e
−k21t + k13e−k31t), (2.6)
When the target concentration increases, the TCI system calculates a new
initial bolus to increase the drug concentration in the central compartment from
the previous blood/plasma target concentration to the new one equation (2.7),
and recalculates the infusion rates associated with the elimination and transfer
processes for the new target, considering the amount of the drug already present
in the peripheral compartments equation (2.8).[60]
ADDLD = V1(NCpt− Cpt), (2.7)
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where τ is the time of Cpt change; m2(τ) (mg) is the amount of anaesthetic
drug in the second compartment at the time of target change and m3(τ) (mg) is
the amount of anaesthetic drug in the third compartment at the time of target
change.
If the target concentration decreases, the TCI system will stop the infusion
until the new blood/plasma target concentration is achieved and restart the infu-
sion at that moment with the new infusion rate obtained from equation (2.8).[4]
However in the real world, it is necessary to consider the limitation of the infu-
sions devices, such as a lack of infinity precision and the maximum infusion rate,
and so continuous adjustments to the infusion rates are necessary.
2.4.2 Pharmacodynamic Modelling
The PK models described on the previous Subsection allows us to predict the
effect-site concentrations of administrated anaesthetic drugs from their infusion
profiles. In this Subsection the PD models are introduced which will relate the
effect-site concentration with the effect that the anaesthetic drug exhibits over
the patient, which is assessed as the degree of depression of the EEG (in the case
of this research project measured by the BIS Vista monitor). It can be described
as what the drug does to the body. The effect-site compartment refers to the PK
model can also be considered as part of the PD model.
The typical method to describe the PD model is through a single variable
Hill curve which is used to estimate a single drug parametric PD model using
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optimization techniques. A multi variable Hill curve is also introduced which is
used to estimate a two drugs PD model considering the drugs interactions.
2.4.2.1 Hill Model - One Drug
The pharmacodynamics of individual drugs are often modeled by a sigmoid Emax
model called Hill curve described by the following equation [28]:





where E0 is the clinical effect when no drug is present, Emax is the maximum drug
effect, Ce50 is the effect-site drug concentration associated with 50% maximal
drug potency, γ is the steepness of the concentration-response curve and Ce is
the effect-site drug concentration.
For the case considered in this research project, where the effect of the anaes-
thetist is assessed though BIS Vista monitor, E0 and Emax will have a value of
100 and 0, respectively. Ce50 and γ are the patient’s dependent parameters to
which there are no widely accepted parameters. In the project, these parameters
are estimated from the clinical data recorded at King’s College London using
least square curve fitting and genetic algorithms optimization.
2.4.2.2 Hill Model - Two Drugs
In 2000, Minto et al. proposed [46] a response surface model, based on the
Hill curve, to describe drugs’ interaction when more than one drug is adminis-
trated. A joint pharmacodynamic model for the co-administration of propofol
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and remifentanil can be described by the following equation [10]:
Effect(Ceprop, Ceremi) = E0










where θ is the ratio of the two drugs defined by equation (2.11); and Uprop and
Uremi are the normalized effect-site drug concentrations of propofol and remifen-












U50(θ) = 1− βθ + βθ2 (2.13)
Such as in the PD model of individual drugs, E0 and Emax will have a value
of 100 and 0, respectively. Ce50,prop, Ce50,remi, β and γ are patient’s dependent
parameters.
2.5 Implementation of the Pharmacokinetic model
in MATLAB
During this research, a three-compartment pharmacokinetic model with effect-
site compartment was implemented for use in simulation studies. Initially, it was
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implemented using MATLAB and Simulink on its continuous representation using
the differential equations which describe the changes of the amount of drug in
each of the three compartments and relate to the plasma concentration with the
effect/site concentration, see Appendix A. This model was implemented with the
model parameters as variables, which permit the simulation of the PK behaviour
of different drugs, and with the possibility to define up to 4 different infusion
rates.
Two different well-known PK models for propofol, Marsh and Schnider models
(tables 3.1 and 3.2), can predict different blood/plasma drug concentrations and
effect-site drug concentrations (Figure 2.6 and 2.7) even using the same infusion
scheme for the same patient. Therefore it is important to analyze these models
and propose adjustments if justified, since the blood/plasma drug concentrations
are related to the effect of anaesthetic agents [60].
Analyzing Figure 2.6 and 2.7, it is possible to observe that the changes in
the infusion rate are reproduced faster in the plasma concentration and effect-
site concentration of propofol with the Schnider model [54] than with the Marsh
model [41]. When a high infusion rate was used for a short time the peak of
blood/plasma concentration of propofol was much higher in the simulation using
Schnider model. This also happens in the effect-site concentration.
Over all the simulation time, it is possible to observe that the plasma and
effect-site concentration of propofol is higher when a Schnider model is used
to estimate the drug concentrations. This is not true only after a decrease of
the infusion rate where the plasma concentration and effect-site concentration is
higher in simulation with the Marsh model. This is due to the slower time of
response in the Marsh model, which makes the decrease of drug concentrations
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slower.
Figure 2.6: Simulated blood/plasma drug concentration (upper graph) and effect-
site drug concentration (bottom graph) for the infusion of propofol 2% (20 mg/ml)
in a patient 50 years old, male, height of 175 cm and weight of 70 kg, with
Marsh and Schnider model with the same infusion scheme. Infusion at 600 ml/h
until second 30, 25 ml/h between second 30 and minute 30, 40 ml/h between
minute 30 to 60 and 15 ml/h from minute 60 until the end, with a total propofol
administrated of 1046 mg.
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Figure 2.7: Simulated blood/plasma drug concentration (upper graph) and effect-
site drug concentration (bottom graph) for the infusion of propofol 2% (20 mg/ml)
in a patient 50 years old, male, height of 185 cm and weight of 85 kg, with Marsh
and Schnider models in continuous and discrete (sampling time of 100 seconds)
time with the same infusion scheme. Infusion at 25 ml/h until minute 15, 50
ml/h between minute 15 and minute 45, 15 ml/h between minute 45 to 90 and 50
ml/h from minute 90 until the end, with a total propofol administrated of 1350
mg.
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2.5.1 Implementation of discrete PK model
Following the implementation of the pharmacokinetic model using MATLAB and
Simulink on its continuous time representation using the differential equations,
an implementation on discrete time was needed to support the simulations of the
controller to be developed, as the aim of this project is to design a automatic
close-loop control system for general anaesthesia to be implemented on a digital
computer. This implementation was achieved using MATLAB routines.
An object representing the continuous time state space model for the PK
model was created in MATLAB. The discretization of the PK model was accom-
plished using the MATLAB function c2d with the method of zero hold order and
a sampling time specified by the user. A study was carried out to verify that the
function c2d converts the continuous time models according to the rules defined
in Subsection 2.4.1.1.
The representation of the simulated concentrations obtained when using the
continuous (lines in blue and red) and discrete (points in blue and red) time PK
model can be observed in Figure 2.7. For the discrete time PK model simulation
a sampling time of 100 seconds was used. It is possible to observe that the
concentrations on the sampling points are exactly the same as those obtained
with the continuous time PK model simulation.
A user interface (Figure 2.8) was created to enable easy access to the PK and
TCI discrete implementations. These tools enable the verification and correction
of inconsistencies in the data recorded at the King’s College Hospital due to
occasional communication issues between ASYS and the infusion pumps.
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Figure 2.8: User interface for PK models and TCI implementations.
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2.6 Summary
In this chapter an overview of the clinical protocol during surgeries used at King’s
College Hospital is presented followed by a description of the clinical setup imple-
mented for data collection. A brief literature review of pharmacological modelling






As mentioned in Section 1.2, the existing populational PD models present a
variety of challenges and the importance of PD models in drug administration
motivates the development of an accurate PD model. Patients’ data (BIS and
haemodynamic parameters) collected at King’s College Hospital are used to sup-
port this investigation. Some published parametric PD models structures based
on the Hill equation and modelling techniques (such as least-squares and genetic
algorithm on data fitting) are studied and their performance compared in terms
of modelling error.
PD modelling for the co-administration of propofol and remifentanil using BIS
as a measure of the drugs’ effect is investigated. SVR, a non-parametric modelling
technique, and the incorporation of patients’ haemodynamic parameters in PD
modelling are also explored. Three PD models implemented by SVRs [56] are
proposed for BIS estimation. The first SVR-based PD model is with single-
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drug input (propofol) while the second one is with two-drug input (propofol and
remifentanil). A third SVR-based PD model considers nCO as an additional
input, as nCO plays an important role in PK/PD modelling [7, 35].
The three SVR-based PD models are trained with the patients’ data in the
induction stage. An algorithm is proposed to model the induction stage of a given
patient’s data. The modelling performance of the three SVR-based PD models
are compared with Hill equation based PD models.
PD models are continuous non-dynamic models, which aim to map PK pre-
dicted effect-site concentrations with clinical effect of the anaesthetic drugs. The
dynamic behaviour of the system is represented by the PK models defined on
section 2.4.1.
3.2 Clinical Data
Clinical data recorded with ASYS as described in Chapter 2 from 42 elderly
patients undergoing major vascular surgery of the lower limbs was used to perform
PD modelling. This population was comprised of 35 males and 7 females, age of
72 ± 8 years, height of 169 ± 10 cm and weight 73 ± 14 kg. Values are presented
as mean ± SD.
The clinical data recorded with ASYS provides predicted effect-site concen-
tration for anaesthetic drugs according to pharmacokinetic models descrived on
section 2.4.1. The PK model’s parameters for a specific drug are usually es-
timated using statistical approaches by measuring the arterial or venous blood
concentration of the drug after a bolus or infusion, in a group of patients or vol-
unteers. These parameters are presented on tables 3.1, 3.2 and 3.3 with age in
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years, height in cm and weight in Kg for the PK models of the hypnotic drug
propofol and the analgesic drug remifentanil. LBM is defined as:
• Males: LBM = 1.1weight− 128(weight/height)2
• Females: LBM = 1.07weight− 148(weight/height)2


















The PK model described in Section 2.4.1 allows us to predict the effect-site con-
centrations of administrated anaesthetic drugs from their infusion profiles. Pre-
dicted effect-site concentrations evaluated by the infusion pumps are available on
the clinical data recorded through ASYS.
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Table 3.2: Parameters for Propofol - Schnider model[54]
Parameter Value
V1(l) 4.27
V2(l) 18.9− 0.391(age− 53)
V3(l) 238
k10(min
−1) 0.443 + 0.0107(weight− 77)− 0.0159(LBM − 59) + 0.0062(height− 177)
k12(min









Table 3.3: Parameters for Remifentanil - Minto model[45]
Parameter Value
V1(l) 5.1− 0.0201(age− 40) + 0.072(LBM − 55)
V2(l) 9.82− 0.0811(age− 40) + 0.108(LBM − 55)
V3(l) 5.42
k10(min
−1) [2.6− 0.0162(age− 40) + 0.0191(LBM − 55)]/V1
k12(min
−1) [2.05− 0.0301(age− 40)]/V1
k13(min






−1) 0.595− 0.007(age− 40)
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Hill equation based PD models described on Section 2.4.2 are estimated for
the 42 clinical data records through least square curve fitting method and GA
optimization.
3.3.1 Support Vector Machine/Regression Model
The problem with PD modelling of the effect of anaesthetic drugs can also be
approached as a non-parametric regression problem. Having this approach in
mind, SVR, a technique based on support vector machine (SVM), was applied to
the clinical data. The basic concept of this technique is to project the input data
using a kernel function into a higher dimensional feature space where a linear
regression problem is obtained [56]. In this work a standard ε-insensitive loss
function was used for the SVR algortihm.
Considering a training dataset S = {(x1, y1) . . . (xm, ym)}, where xi ∈ Rd
is the input sample and yi ∈ R is the observed output value, the ε-insensitive
SVR technique for linear functions aims to find function f(x) = 〈w, x〉+ b which
has at most ε deviation from y for all data points S, where w is the parameter
defining the hyperplane, b is the bias and 〈., .〉 is the inner product operator.
However, sometimes such function f(x) does not exist and the introduction of
slack variables (ξi, ξ
∗
i ) is necessary to allow certain data points to violate the
constraints at a cost C ∈ R. A solution to the described problem is achieved by
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‖w‖2 + CΣmi=1 (ξi + ξ∗i )
subject to

yi − 〈w, xi〉 − b 6 ε+ ξi










(αi − α∗i )〈xi, x〉+ b, (3.2)
where αi and α
∗
i are the Lagrangian multipliers obtained by solving the problem
described by equation (3.1). The subset of the training data points for which
αi − α∗i 6= 0, are called the support vectors and they are enough to completely
describe the SVR solution, decreasing the computational requirements this way.
This ε-insensitive SVR technique for linear functions can be extended to non-
linear functions by applying a kernel mapping to project the input data into a
higher dimension feature space where the problem has linear characteristics and
can be approached by the described method. As all the described method can
be expressed in terms of inner-product between the training dataset, a kernel
function (K(xi, xj)) matching the inner-product on the feature space is enough





(αi − α∗i )K(xi, x) + b, (3.3)
To a kernel function (K(xi, xj)) matching the inner-product on the feature
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space, it needs to obey Mercer’s Theorem [56].
3.4 Model Adequacy Index
As the SVR modelling technique is a non-parametric modelling method, analysing
the modelling performance only in terms of the mean absolute error (MAE) on
the testing dataset is not enough. The modelling performance should be analysed
in terms of error, in training and testing datasets, and in terms of the adequacy
of the output signal of the generated model as an estimator of the clinical effect
of the anaesthetic drugs. Taking these points into consideration, a new measure
of Pharmacodynamic modelling performance should be created to evaluate and
compare the different modelling techniques.
To ensure the adequacy of the output signal of the generated model as an
estimator of the clinical effect of the anaesthetic drugs, both signals, the model
estimated output and the BIS signal, should have similar behaviour. In this
study the clinical effect of the anaesthetic drugs is evaluated by the BIS signal
which ranges from 0 to 100, and it decreases with the increase in the anaesthetic
drugs concentration, when no other factors are taken in consideration. The ex-
pected value for the BIS signal on a fully awake patient without the presence of
anaesthetic drugs is near 100.
From these known behaviours the following index was created to evaluate
pharmacodynamic modelling performance.
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3.4.1 Empirical knowledge of the effect signal
To assess the adequacy and performance of the estimated pharmacodynamic mod-
els the known characteristics and expected behaviour of the BIS signal should be
taken into account and verified against the estimated models.
As previously described BIS signal ranges from 0 to 100 and is expected to
be near 100 when no anaesthetic drug is present and the patient is awake, and
to decrease up to 0 as anaesthetic drug presence increases, i.e. BIS index should
be a decreasing function of the concentration of anaesthetic drug. As such it is
expected for a BIS value to be 0 for high concentrations of anaesthetic drug. The
hypnotic drug used in this study was propofol to which an estimated effect-site
concentration of 18 µg/l has an expected BIS value of 0 as it is well above usual
doses [44].
3.4.2 Description of Model Adequacy Index
To validate the estimated models though the SVRs technique as adequate phar-
macodynamic models each estimated model was evaluated in 4096 points in the
range range 0 and 20 for the various possible inputs. For example, in the models
estimated using the single-drug SVR technique which only has propofol effect-site
concentration as input, the effect of the propofol was evaluated with the output
of the estimated PD model on 4096 points for the propofol effect-site concentra-
tions between 0 and 20 µg/ml, uniformly spaced. However, in the case of the the
models estimated using the nCO adjusted multi-drug SVR technique which has
propofol, remifentanil effect-site concentration and nCO as input, the effect of the
anaesthetic drugs was evaluated with the estimated PD model on 4096 points,
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uniformly spaced on a grid sense, i.e. for all the possible combinations of 16 values
of propofol effect-site between 0 and 20 µg/ml, 16 values of remifentanil effect-
site between 0 and 20 ng/ml and 16 values of nCO between 0 and 20 l/min,
uniformly spaced. From these 4096 obtained values a Model Adequacy Index
(MAI) was proposed to evaluate the performance and validity of the SVR-based
PD model.
The MAI tests various statistics obtained from the 4096 points, which test
the adequacy of the models’ outputs as BIS signal. These statistics are percent-
ages of the number of estimated points without output below 0 and −10 and
above 100 and 110. Another statistic used is the percentage of points with an
output within the range of 0 to 100 which satisfy the condition of BIS being a
decreasing function of the concentration of propofol, i.e. the percentage of points
for which the estimated effect is lower than the estimated effect for the imme-
diate previous point with higher propofol effect-site concentration and the same
remifentanil effect-site concentration and nCO, if applicable. The last statistic
used is the Deviation, which assess the deviation from the expected BIS value
of 0 on high concentrations of propofol. The absolute average output (AAO) is
the absolute average of the estimated effect for the points with the 10% higher
values of the evaluated propofol effect-site concentration, which will consist of the
absolute average of the the estimated effect for all the validation points obtained
from a propofol effect-site concentration between 18 and 20 µg/ml. Deviation is
calculated by assessing the displacement of AAO against the expected value of
0 using equation (3.4). Deviation value was expressed as a percentage for the
46






Table 3.4 presents the weights used for each component of the model adequacy
index.
Table 3.4: Weights of the Model Adequacy Index statistics.
Condition Weight
% of points 6< 0 1
% of points 6< -10 10
% of points 6> 100 1
% of points 6> 110 10






Clinical data from 42 vascular surgeries under general anaesthesia were collected.
Collected BIS index, propofol and remifentanil concentrations trends were vi-
sually analyzed to access times for stable pre-induction baseline readings, i.e.
marking an interval of stable clinical signals before starting the infusion of anaes-
thetic drugs. From the observations of the visual analysis, it was also decided to
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mark the end of induction 8 minutes and 20 seconds (100 samples) after the first
reading of BIS index below 60. The data recorded up to this mark will constitute
the training dataset, while the remaining surgery data will be the testing dataset.
Average BIS index on pre-induction baselines was 93.2 ± 7.3 and nCO was
6.9 ± 2.7 l/min. Average duration of induction was 15.2 ± 3.2 minutes and total
amount of propofol and remifentanil infused during induction were 2.55 ± 0.67
mg/kg and 1.5 ± 0.37 µg/kg, respectively.
Most of the considerable changes in BIS index were verified during the in-
duction period, maintaining a stable reading during maintenance phase as this
was the main control variable used by the anaesthetist as it can be observed on
Figure 3.1. At pre-induction baseline, before drugs infusion, BIS index presents a
high value, between 90 and 100. With the infusion of anaesthetic drugs and their
effect-site concentration increase, BIS values start to decline to the 40 to 60 inter-
val, where they are maintained after induction. A 5 fold variation in inter-patient
propofol and remifentanil effect-site concentrations requirements was needed to
maintain BIS within target as shown by Figure 3.1.
From Figures 3.2 and 3.3 which present signal traces from two surgeries, it
is observed that dissimilar anaesthetic drugs effect-site concentrations might be
necessary to maintain a BIS signal within the target boundary of 40 to 60. It
is also observed that even though the anaesthetist was aiming to maintain BIS
within 40 to 60 limit it was not always possible to achieve and there were a few
periods where BIS value was outside these. This is particularly noticeable on
Figure 3.3 from minute 120 where BIS show higher variation.
Simultaneously with the decrease in BIS values, a decrease in nCO is verified
in most of the 42 analysed cases. This can be easily observed for case 1 in Figure
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Figure 3.1: Clinical data traces for all 42 vascular surgeries. Zero minute was
set 100 samples (8 minutes and 20 seconds) following BIS first reading below 60.
Top: BIS values; Middle: Propofol (Prop.) and remifentanil (Remi.) effect-site
concentrations; Bottom: nCO values.
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Figure 3.2: Clinical data trace for case 1. Zero minute was set 100 samples (8
minutes and 20 seconds) following BIS first reading below 60. Top: BIS val-
ues; Middle: Propofol and remifentanil effect-site concentrations; Bottom: nCO
values.
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Figure 3.3: Clinical data trace for case 2. Zero minute was set 100 samples (8
minutes and 20 seconds) following BIS first reading below 60. Top: BIS val-
ues; Middle: Propofol and remifentanil effect-site concentrations; Bottom: nCO
values.
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3.2.
3.5.1 Pharmacodynamic Modelling - Performance Results
Parametric modelling supported in the single and multi-variable Hill model was
considered given in Section 2.4.2. Least square (LSQ) curve fitting and genetic al-
gorithm (GA), with two cost functions - Sum of square error (SSE) equation (3.5)
and Mean absolute error (MAE) equation (3.6) - were used. LSQ and GA find the
optimal Ce50 and γ parameters for the single Hill model, or Ce50,prop, Ce50,remi,
β and γ parameters for multi-variable Hill model minimizing the respective cost











where m is the number of points of the training dataset; Effect(Cei) is the
estimated effect by the PD model of the anaesthesia on the patient; and BISi is
the effect of the anaesthesia on the patient measured by the BIS Vista monitor
on the ith patient.
The second technique applied was SVR using a diverse combination of kernels
and C values, for the three inputs configurations estimated - one drug (propofol),
two drugs (propofol and remifentanil) and two drugs with nominal cardiac output
in order to estimate the function f(x) defined in equation (3.3). The obtained
results and some observations are made below. SVR modelling was performed
using polynomial, gaussian radial basis (RBF), exponential radial basis, spline
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and anova spline kernel functions, C value of 1, 10, 100, 500 and 1000, and  of
2.
The recorded clinical data is presented in Figure 3.4 together with BIS values,
propofol and remifentanil effect-site concentration and nCO during one vascular
surgery. Some of the estimated PD models for this case are also presented, in-
cluding all PD models based on single and multi variable Hill equations and the
models estimated using the SVR technique under a RBF kernel and C value of
10, as examples of the different PD models estimated by the various techniques.
Figure 3.4 shows top recorded BIS values (black line) and BIS estimations
from the estimated PD models. Estimated BIS are from PD modelling with
Hill - LSQ/GA-SSE (magenta solid line) single-drug Hill model by least square
curve fitting and genetic algorithm with sum square errors cost function; Hill -
SMAE (yellow solid line) single-drug Hill model by genetic algorithm with mean
absolute errors cost function; Hill - MLSQ (cyan dashed line) multi-drug Hill
model by least square curve fitting; Hill - MSSE (magenta dashed line) multi-
drug Hill model by genetic algorithm with sum square errors cost function; Hill
- MMAE (yellow dashed line) multi-drug Hill model by genetic algorithm with
mean absolute errors cost function; SVR - S (blue solid line) single-drug SVR
model; SVR - M (red solid line) multi-drug SVR model; SVR - MCO (green solid
line) nCO adjusted multi-drug SVR model. Propofol and remifentanil predicted
effect-site concentrations are shown in the middle and nCO values at the bottom.
3.5.1.1 Single-Drug (Propofol) Hill Model
Similar estimated parameters were obtained by LSQ and GA methods when mod-
elling BIS using single-variable Hill model (effect-site propofol concentration is
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Figure 3.4: Clinical data traces and estimated PD models for case 3. Zero minute
was set at 100 samples (8 minutes and 20 seconds) following BIS first reading
below 60, which match the end of the training dataset and start of testing dataset.
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Table 3.5: Parameters results for Hill Models.
Model Method γ Ce50prop Ce50remi β
One Drug LSQ 1.76 ± 0.78 2.65 ± 0.83 —– —–
One Drug GA SSE 1.76 ± 0.78 2.64 ± 0.8 —– —–
One Drug GA MAE 1.73 ± 0.7 2.7 ± 0.95 —– —–
Two Drugs LSQ 5.56 ± 7.48 5.97 ± 5.27 42.84 ± 36.17 1.5 ± 1.62
Two Drugs GA SSE 3.11 ± 1.62 4.25 ± 2.09 23.2 ± 5.39 1.71 ± 0.87
Two Drugs GA MAE 2.92 ± 1.4 4.52 ± 2.58 23.3 ± 5.38 1.68 ± 0.85
the only model input) (Table 3.5). LSQ and GA SSE presents the same mean
absolute errors on the various sub-set of data analysed, having a 4.89 ± 1.76
training MAE and 11.89 ± 7.47 testing MAE, see Table 3.6. A smaller error
(4.76 ± 1.69) is obtained in training data when the GA MAE method is used in
contrast to LSQ or GA SSE, but with higher testing errors (12.17 ± 7.64).
3.5.1.2 Multi-Drug (Propofol and Remifentanil) Hill Model
When BIS modelling is performed using the multi-variable Hill model (using
propofol and remifentanil effect-site concentration as inputs), different results
and performances can be observed in Tables 3.5 and 3.6. The least square curve
fitting method presents slightly better performance in the training dataset, but a
worse performance in the testing dataset, when compared to GA methods. Also
to be noted are the considerable differences that can be observed between the
estimated parameters with the LSQ or GA techniques. Standard deviation of the
estimated parameters is substantially smaller when a GA technique is applied in
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3. SVR-BASED PD MODELLING
comparison with LSQ, with a reduction of 50% (5.27 to 2.58) to 80% (36.17 to
5.38).
3.5.1.3 Single-Drug (Propofol) SVR Model
Diverse results were obtained with the single-drug SVR modelling, having errors
in the training dataset varying from 2.27 ± 0.93 to 13.57 ± 4.16 and from 8.69
± 6.90 to 14.73 ± 6.83 in the testing dataset, depending on the kernel function
and C value used. Detailed results are presented in Table 3.7, 3.8, 3.9, 3.10 and
3.11.
Analyzing modelling performance as mean absolute error (MAE) in the testing
dataset, it is not clear which is the best choice for kernel function and C value,
as the kernel function with the best performance also presents bad performances
for different C values, and the same can be observed in relation to C value.
Performance in terms of training and testing error of single-drug SVR mod-
elling compared with parametric Hill modelling is highly dependent in the kernel
function and C value used, and no inference can be easily obtained from it.
3.5.1.4 Multi-Drug (Propofol and Remifentanil) SVR Model
As with the single-drug SVR modelling, varied results were obtained with multi-
drug SVR modelling, with training errors varying between 1.93 ± 0.79 and 13.37
± 4.37m and testing errors from 10.80 ± 4.86 to 53.27 ± 69.74, having the same
outcome when compared to the multi-drug Hill modelling. Detailed results are
presented in Table 3.12, 3.13, 3.14, 3.15 and 3.16.
However in this case, it is clear that the polynomial kernel function presents
the worst performance in terms of mean absolute errors in the testing dataset, and
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3. SVR-BASED PD MODELLING
that, in general, the Gaussian radial basis, exponential radial basis are the kernel
functions with better performances, independent of the C value. If focusing only
on the results for only these two kernel functions, opposite performance results
are observed for each kernel in relation to C value, performance increases with
the increase of C value in the case of the exponential radial basis, and decreases
for the Gaussian radial basis kernel function.
3.5.1.5 nCO Adjusted Multi-Drug (Propofol and Remifentanil) SVR
Model
When multi-drug and nCO SVR modelling was applied to the clinical data, train-
ing errors between 1.59 ± 0.27 and 16.31 ± 4.25 and testing errors from 9.45 ±
3.63 to 76.11 ± 109.37 were obtained. As for the multi-drug SVR modelling, the
polynomial kernel function presented the worst performance and the Gaussian
and exponential radial basis kernel functions had the best performances. The
relation between the value of the C value and the kernel function is the same as
observed in the previous modelling case, with the exception of the combination
of the exponential radial basis kernel function and the C value of 1, which has
a better performance than any other models obtained with the kernel. Detailed
results are presented in Table 3.17, 3.18, 3.19, 3.20 and 3.21.
If focusing only on modelling results for the Gaussian and exponential radial
basis kernel functions, the nCO adjusted multi-drug modelling seems to have
better performance when compared to multi-drug modelling, but that advantage
disappears with increase of the C value.
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3. SVR-BASED PD MODELLING
3.5.2 Results of the Model Adequacy Index
The MAI was assessed for all the models obtained using the SVR modelling
technique. For the pharmacodynamic models obtained using either single-drug
Hill Model or multi-drug Hill, the MAI was not assessed as these are parametric
models based on a sigmoid curve which complies with all the BIS characteristics
to which the MAI was developed to assess compliance.
Tables 3.22 to 3.26 presents a summary of the obtained MAI for all the Phar-
macodynamic SVR models grouped by model structure, kernel and C value. It
shows the minimum, maximum, mean and standard deviation (SD) of the MAI
for each group of 42 estimated Pharmacodynamic SVR models as well totals per
model structure and kernel.
The overall MAI minimum and maximum obtained were 24% and 100%, re-
spectively, while the mean value was 52%. Similar results are obtained when
considering the results per model structure, and no difference is observed be-
tween the three model structures.
Analysing the results per kernel, only the RBF kernel has the maximum MAI
of 100% and a mean above 90% while the remaining kernels do not present any
MAI above 60%. While the exponential radial basis function (ERBF) kernel
presents the MAI’s highest minimum and the smallest standard deviation of all
the kernels used, its mean value is 59% and never achieves higher values of com-
pliance above 60%. This is due mainly to an extremely low value of Deviation,
reflecting the inability of the estimated Pharmacodynamic SVR models achieving
the BIS values of zero in high concentrations of propofol, as presented in figure
3.5.
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3. SVR-BASED PD MODELLING
Figure 3.5: Effect surfaces (left) and contour plot (right) for case 3 estimated
multi-drug SVR model with C value of 10 and rbf kernel (top line) or erbf kernel
(bottom line), obtained from 4096 points evaluated to assess model adequacy
index.
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Regardless of all three model structures implemented showing similar MAI
results considering all Pharmacodynamic SVR models estimated, if only the mod-
els estimated with a RBF kernel function are considered, an adequacy difference
arises between model structures. The adequacy of the estimated models increases
with the complexity of the model structures, having the one drug model the low-
est adequacy of 87% ± 14%, and the two drugs with nCO the highest with 97%
± 3%.
Finally, looking at the detail of Tables 3.22 to 3.26, it is possible to observe
that the Pharmacodynamic model adequacy decreases with the increase of the C
values of the SVR modelling.
From these results, the most appropriate kernel would be the RBF. These re-
sults need to be analysed in conjunction with the performance results to determine
the best combination of model structure, kernel and C values for Pharmacody-
namic SVR modelling.
3.5.3 Comparison between Adequacy and Performance of
the SVRs
In this Subsection we will focus our analysis of the suitability of SVR as a PD
modelling technique in the performance of the estimated models in terms of MAE
in the training and testing datasets, which is presented in Tables 3.7 to 3.21 while
considering model adequacy. The best estimated Pharmacodynamic model would
be the one which presented the highest adequacy, assessed by the highest MAI,
and the best performance, assessed by the lowest training and testing MAE.
With the consideration of the results presented in the previous subsection, it
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can be established that only SVRs with an RBF kernel present an acceptable
adequacy level for the intended PD modelling. From Tables 3.7 to 3.21 it is
possible to observe that the training MAE decreases with the increase of the C
value. There is a significant training MAE decrease between the C values of 1
and 10, in all the RBF SVR structures implemented, but much smaller with the
remaining C values. In contrast with the training MAE behaviour, the testing
MAE increases with the increase of the C values, however no significant change
is observed for the C values of 1 and 10, and their values are similar within the
various C values used.
When taking into consideration these observations with the observation that
the adequacy decreases with the increase of the C value, in the previous subsec-
tion, it can be asserted that the model estimated though the SVR technique with
the RBF kernel and C value of 10, is the most suitable as an SVR PD model. This
assertion is obtained by considering the described observation, it is necessary to
compromise between the model adequacy and performance.
3.6 Discussion
3.6.1 Hill Models
The results for the modelling of BIS using the single and multi-variable Hill
models are presented in Tables 3.5 and 3.6.
From the three techniques used to estimate Hill equation’s parameters, GA
with MAE as cost function proved to be the most appropriate. This is reflected
by smaller training and testing errors in conjunction with the smaller standard
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deviation on the Hill model parameters. The smaller standard deviation on the
model parameters indicates that GA produce a model with smaller inter-patients
variability, which is an advantage for the generalization of the models.
When comparing the single with the multi-variable Hill model, it is observed
that the modelling of the clinical effect of the anaesthetic drugs using the multi-
variable Hill presents a better, i.e. smaller, training error, but a considerably
worse performance in the testing data.
In contrast with the SVR modelling technique, all the estimated Hill models
have full adequacy as Pharmacodynamic models, which is insured by the para-
metric nature of the technique and the limits established for the Hill parameters.
3.6.2 SVR Models
As described in Section 3.5, the performance of the estimated SVR models is
highly diverse and dependent on the model structure, kernel and C values, and
therefore there is no clear better model in terms of performance. However when
the Pharmacodynamic model adequacy requirement is taken in to consideration,
a few features become evident.
As stated in Section 3.5 only the estimated models using a RBF kernel can
be considered as adequate Pharmacodynamic models, and when adequacy and
performance are analysed in conjunction, it can be concluded that the C value
of 10 is the most suitable for the necessary compromise between adequacy and
performance.
The observation that adequacy decreases with the increase of the C value
can be explained by the fact that a high C value estimates a model with smaller
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margins, forcing a high number of samples to be matched by the estimated model.
As the BIS signal is noisy, this can create a model that is too sensitive.
For the combination of RBF kernel with a C value of 10, all three SVR struc-
tures implemented present a similar performance, however adequacy is improved
with the increased complexity of the SVR structure. Therefore, the Pharmacody-
namic models estimated though the SVR technique with a RBF kernel, C value
of 10 and with the two drugs plus the cardiac output as model inputs, has the
best adequacy.
3.6.3 Comparison between Hill Models and SVR Models
From the performance and adequacy analysis of the various estimated SVR Mod-
els, the models using the RBF kernel and the C value of 10 are the most suitable
as a PD model. The performance of two of these SVR models can be compared
with the performance of the PD models obtained through the Hill equation. For
the SVR structure of two drugs with nCO information, a direct comparison to
Hill models is not admissible since they do not consider nCO information.
In the first case, where the anaesthetic effect is modelled based solely on the
effect-site concentration of propofol, one drug model, we can observe from Tables
3.6, 3.7, 3.8, 3.9, 3.10 and 3.11 that the SVR technique presents a smaller train-
ing error compared with all three estimation methods used on the Hill equation
structure. However, the testing error is slightly higher, although with a smaller
standard deviation.
The second model structure which allows direct comparison between the Hill
and SVR modelling techniques is the case where the anaesthetic effect is modelled
84
3. SVR-BASED PD MODELLING
based on the effect-site concentrations of propofol and remifentanil. As in the
previous case, the SVR technique has a smaller training error compared with the
Hill methods. However the performance results obtained on the testing dataset
are considerably better in the PD models estimated using the SVR technique. The
mean absolute error in the testing data for the SVR technique (using RBF kernel
and a C of 10) was 12.2 ± 6.74 (mean ± SD) against 28.35 ± 15.46 and 31.23 ±
17.7 with the Hill structure. This result suggests that the SVR technique has a
better generalization property than the Hill model, and is capable of extracting
more information from the training data, namely on the synergetic interaction
between the drugs.
While a better performance is obtained by the SVR modelling technique,
these models do not present a 100% adequacy as a PD model in contrast with
the Hill modelling techniques. However the estimated SVR models compared in
this section do present a high level of adequacy (see Tables 3.22 to 3.26) and this
can be adjusted with minor model output post-processing.
3.6.4 nCO adjusted Support Vector Regression Model
One of the SVR model structures used in this study makes use of the cardiac
output information in addition to the effect-site concentrations of propofol and
remifentanil. Tables 3.12 to 3.26 show that its performance and adequacy is
similar to the case where the SVR model structures incorporate only the two
effect-site concentrations (with RBF kernel and a C value of 10).
No significant performance differences can be found between these two model
structures for the remaining C values with RBF kernel. Adequacy of the SVR
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model structure using the nCO information also decreased with the increase of
the C values, as in the case of the SVR model structure using only the effect-site
concentrations of propofol and remifentanil. However, the adequacy decrease in
relation to the C value increase with the SVR model structure using the nCO
information, is smaller than that of the SVR model structure with two drugs
without the nCO information.
As previously discussed, the nCO may have an important role to play in the
PK/PD modelling. This is based on previous studies where a strong correlation
between propofol requirements and nCO was found in vascular patients and in
published studies such as Kurita et al.[35] where an inverse relation between
nCO and plasmatic propofol concentration in swine is demonstrated. Considering
this and that the effect-site concentration used as inputs for the PD models are
estimated through a PK model solely dependent on the infusion of propofol and
patients’ weight, which does not account for change in the nCO, it was considered
relevant to incorporate it in the PD modelling.
Considering the above, in our opinion it would be appropriate to have the nCO
in consideration when constructing a controller for the induction and maintenance
of intravenous anaesthesia. The inclusion of nCO in the control law will make
it more robust to disturbances and might present a better performance when
compared to a controller without these considerations.
3.7 Summary
In this chapter, we have studied the modelling of the effect of anaesthetic drugs
in patients under general anaesthesia during surgery. Two modelling approaches
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were applied to establish PD models. The first approach consisted of creating
a parametric model based on the published equation of Hill. Support vector
regressors were used in the second approach as a non-parametric technique which
would enable the incorporation of others variables in the modelling process such
as cardiac output.
From our results we can conclude that the SVR modelling technique with
an RBF kernel presents a better performance compared to the parametric Hill
modelling technique, for PD modelling based on predicted effect-site concentra-
tions of propofol and remifentanil. However one needs to be aware that the SVR
modelling technique does not have a 100% adequacy in contrast with the Hill
modelling technique.
It was also found that incorporating the cardiac output in the modelling pro-
cess using the SVR modelling technique has not reduced the performance of the
estimated Pharmacodynamic models and has improved the adequacy. This is of
extreme importance from a clinical perspective, since the PK models are based on
estimated and not real drug concentrations (which are impossible to measure on-
line). It is well proven that variations in nCO change the drugs’ metabolism (its
PK characteristics) [35], therefore a model that can predict PK and subsequent
PD changes has a positive impact on the description of drug effect. Research has
shown that patient heamodynamic alterations have an impact on the BIS index
in response to alterations of propofol PK [29]. The inclusion of nCO allows for
the SVR structure model to adjust itself to changes in the PK of the drugs during
a surgical procedure, and will allow for a better control of the drug effect (in this
case the EEG response measured by BIS). This adds great refinement to the tra-
ditional PK/PD model and would also allow automatic adjustment of propofol
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infusion rates as the cardiac output falls. This may happen, for example, during
major haemorrhage which is a major adverse effect of surgery.
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Chapter 4
Control of Anaesthesia using PK
and PD models
4.1 Introduction
Due to the advantages of automatic closed-loop control, in this chapter, the aim is
to implement closed-loop control for the anaesthesia model. The performance of
controllers is ensured by optimization and tested by simulation. For the PK/PD
model used in this thesis, while an existing anaesthesia PK model is utilized, the
parameters of the PD model are especially obtained from clinical data collected
from 42 patients presented in Chapter 3.
Following the same design procedure, these tailor-made controllers can be re-
designed for other patients as long as clinical data have been collected. In the
PK/PD model, the co-administration of both propofol and remifentanil is inves-
tigated. To realize the drug administration, it is proposed to use two strategies:
two fuzzy PID controllers and one fuzzy PID controller with scaling factors. For
89
4. CONTROL OF ANAESTHESIA USING PK AND PD MODELS
each group of strategies, linear PID controller, type-1 (T1) fuzzy PID controllers
and interval type-2 (IT2) fuzzy PID controllers are designed. To draw a dis-
tinction from existing IT2 fuzzy PID controllers, IT2 fuzzy PID controllers is
combined with GA. All PID gains, scaling factors and parameters of membership
functions are optimized by GA in an oﬄine manner subject to a performance
index (cost function) which quantifies the performance of the controllers. A BIS
training profile is employed for training purposes which sets different local targets
for regulation considering the real anaesthesia situation. The trained PID control
strategies are tested with a testing profile to verify their performance in unseen
working conditions. Comparisons are made among all controllers to demonstrate
the characteristics of each control strategy.
The following sections are organized in this sequence: in Section 4.2, a mul-
tivariable anaesthesia model used in this chapter is described; in Section 4.3, the
control background of linear PID controller, T1 fuzzy PID controllers and IT2
fuzzy PID controllers is introduced; in Section 4.4, all the control strategies and
overall procedure and necessary information of the simulation are discussed; in
Section 4.5, the simulation results are provided and comparison and analysis are
carried out; finally, in Section 4.6, a conclusion for this chapter is drawn.
4.2 Multivariable Anaesthetic Modelling
In this section, a anaesthetic model with two drugs is introduced. As shown
in Figure 4.1, the anaesthesia model consists of the target controlled infusion
(TCI) system, the PK model, and the PD model, where Cptprop and Cptremi are
plasma concentration targets, Ip and Ir are infusion rates, Ceprop and Ceremi are
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effect-site concentrations, and the subscript prop and remi are for propofol and
remifentanil, respectively. Details of each TCI and PK modules are described in
Subsection 2.4.1.2 and 2.4.1, respectively. The PD module is a two drugs Hill-
based PD model as described in Section 2.4.2 and its parameters obtained as

















Figure 4.1: A block diagram of multivariable anaesthesia model.
4.3 PID Controllers
In this section, 3 types of PID controllers, namely linear PID controller, T1 fuzzy
PID controller and IT2 fuzzy PID controller, are introduced. These 3 types of
PID controllers are employed to regulate the output BIS index of the anaesthesia
model.
4.3.1 Linear PID controller
A linear PID controller is shown in Figure 4.2, which consists of 3 elements,
namely proportional, integral and derivative blocks. The output of the linear
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PID controller in discrete time is given as







where tk = k∆tk, k = 0, 1, 2, . . . , is the sampling time; ∆tk is the interval of
sampling time; e(tk) ∈ < is the input; u(tk) ∈ < is the output; KP ∈ <, KI ∈ <











Figure 4.2: A block diagram of linear PID controller.
4.3.2 Type-1 Fuzzy PID Controller
In view of the linear PID controller [6], as the proportional, integral and derivative
gains are constant, it is not able to handle well a highly nonlinear system. It
motivates the use of T1 fuzzy PID controller [12, 13] of which the gains change
according to the operating domains. By applying different sets of gains in different
operating domains, a more appropriate PID controller is employed to deal with
the nonlinear system resulting in an improvement of control performance.
A T1 fuzzy PID control system is shown in Figure 4.3, which consists of a T1
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fuzzy PID controller and a patient’s model (detailed in Figure 4.1) connected in
a closed loop. Unlike the linear PID controller having a set of constant gains, the
T1 fuzzy PID controller has a fuzzy inference system providing a set of feedback













KP , KI , KD
+
−
Figure 4.3: A block diagram of fuzzy PID control system.
The behavior of the fuzzy inference system is governed by a set of fuzzy rules
of the following format:
Rule i: IF x1(t) is M
i
1 AND · · · AND xΨ (t) is M iΨ
THEN y(x(t)) = yi, (4.2)
where xj(t), j = 1, 2, . . ., Ψ , is a linguistic variable; M
i
j , j = 1, 2, . . ., Ψ , is
the fuzzy term corresponding to the linguistic variable xj in the i
th rule; Ψ is a
positive integer; y(x(t)) is the output of the fuzzy inference system; and yi is the
singleton membership function corresponding to the ith rule. The inferred output
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wi(x(t)) = 1, (4.4)











where p > 0 denotes the number of rules; wi(x(t)) is the normalized grade of
membership; µM iα(x(t)), α = 1, 2, . . ., Ψ , is the grade of membership correspond-
ing to the fuzzy term M iα.
The output of the fuzzy inference system equation (4.3) is employed to re-
place the gains of the linear PID controller turning it to become a T1 fuzzy PID
controller. More precisely, 3 fuzzy inference systems are required to implement
a T1 fuzzy PID controller. The outputs of the 3 fuzzy inference systems will be
employed as KP , KI and KD. Consequently, the PID gains are no longer con-
stant but dependent on the operating condition characterized by the membership
functions.
94
4. CONTROL OF ANAESTHESIA USING PK AND PD MODELS
4.3.3 Interval Type-2 Fuzzy PID Controller
Type-2 (T2) fuzzy sets [25, 30, 36, 37] demonstrate a superior characteristic hand-
ing uncertainties compared with the T1 fuzzy sets. Uncertainties are captured
by the lower and upper membership functions which form the footprint of uncer-
tainty (FOU). A T2 fuzzy inference system can be considered as a set of infinite
number of T1 fuzzy inference systems. Consequently, a T2 fuzzy inference sys-
tem is able to outperform the T1 fuzzy inference system in terms of reasoning
and generalization capability. In general, the defuzzification process for general
T2 fuzzy sets is computational demanding. By using IT2 fuzzy sets [43], the
computational demand can be significantly reduced.
By employing interval fuzzy sets for the T1 fuzzy inference system equation
(4.3), it becomes an IT2 fuzzy inference system. The behaviour of an IT2 fuzzy
inference system is described by a set of rules of the following format:
Rule i: IF x1(t) is M˜
i
1 AND · · · AND xΨ (t) is M˜ iΨ












, i = 1, 2, . . . , p, (4.9)
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µM˜ iα(x(t)) ≥ 0, (4.11)
µM˜ iα(x(t)) ≥ µM˜ iα(x(t)) ≥ 0, (4.12)
wi(x(t)) ≥ wi(x(t)) ≥ 0, (4.13)
yi ≥ yi ≥ 0,∀ i, (4.14)
in which wi(x(t)), wi(x(t)), µM˜ iα
(x(t)) and µM˜ iα(x(t)) denote the lower grade of
membership, upper grade of membership, lower membership function and up-
per membership function, respectively. Using the center-of-set type reducer, the















where yl and yr can be obtained using the Karnik-Mendel (KM) algorithms [42].
96
4. CONTROL OF ANAESTHESIA USING PK AND PD MODELS





The IT2 fuzzy PID control system[18] can be represented by Figure 4.3 as
well of which the PID gains are given by the outputs of 3 IT2 fuzzy inference
systems.
4.4 Simulation Design
In this section, the simulation environment is presented. First, we design the
training profiles and testing profiles which all controllers need to deal with. The
purpose of selected target profiles is described. Then different control strate-
gies are provided for comparison. For fuzzy control strategies, the approach to
determine fuzzy rules is explained. Finally, the procedure of using GA for opti-
mization is described, and a performance index is designed as the cost function
for optimization.
4.4.1 Target Profiles
A training profile as shown in Figure 4.4, which is a series of BIS values required
for an appropriate DOA, is employed for the training of the PID control strategies
using GA. It defines the target BIS values in different periods that a PID control
strategy has to achieve. After the training, a testing profile as shown in Figure
4.5 is employed to verify whether or not the trained PID control strategies are
able to control the BIS value to reach some targets subject to different operating
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conditions.


















Figure 4.4: Training profile.


















Figure 4.5: Testing profile.
Clinically, the induction process starts with BIS(tk) = 98. As a result, the
initial condition for the simulation is BIS(0) = 98 and the target profile begins by
BISt(tk) = 98, where BISt(tk) is the target BIS at sampling time tk. At tk = 120
seconds, the induction is executed and BISt(tk) = 50. Since the induction period
is short when compared with the maintenance period, there is not much differ-
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ence during induction in terms of control performance between various control
strategies. Thus, we use two linear PID controllers for two drugs to drive the
BIS from 98 to 50. By trial and error, the PID gains are predefined, and it is
guaranteed that BIS(1000) is around 50 and the maintenance process starts from
tk = 1000 seconds.
At tk = 1000 seconds, designed controllers replace the predefined controller
to achieve the maintenance process. For a suitable anaesthesia, it is required
that BISt(tk) = 50 and an acceptable range is BIS ∈ [40, 60]. Hence, the control
objective is to maintain the BIS value within [40, 60]. In order to make the
control difficult enough to test various control strategies, more targets are added
into the profiles such as BISt(tk) = 80, tk ∈ [2000, 4000) and BISt(tk) = 20, tk ∈
[6000, 8000) in Figure 4.4.
As for the recovery process, since it is not allowed take the drug out of patients,
the cease of controllers is the only and fastest option. These will also not exist an
overshoot because the target BIS is the maximum value. Therefore, all controllers
will perform the same at this stage. It is not necessary to design controllers for
the recovery process which is thus not included in the target profiles. It is noted
that although the induction process is not under comparison, we cannot ignore
it. The reason is that it is difficult to find all model parameters describing the
state of BIS(tk) = 50. On the other hand, the parameters for BIS(tk) = 98 are
known and it is easy to start from this initial condition.
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4.4.2 Control Strategies
This chapter, follows the objective of comparing different control strategies to
achieve a better control performance. All six control strategies are listed in Table
4.1. These six cases can be separated into two groups: in the two-controller Cases
1 to 3 and one-controller Cases 4 to 6. In the two-controller cases, we control
each drug with an independent PID controller offering control outputs up(tk) and
ur(tk). In one-controller cases, however, the control output of the PID controller
is divided into two control outputs by two scaling factors αr and αp. Apparently,
the parameters of these two divided controllers are constrained by the ratio of
these two factors. Theoretically, this constraint leads to conservativeness and
makes the performance worse than the performance in two-controller cases. Nev-
ertheless, one-controller cases have fewer parameters to be determined resulting
in lower computational demand, faster convergence in the training process and
lower implementation cost for the PID control strategies.
100
4. CONTROL OF ANAESTHESIA USING PK AND PD MODELS
Table 4.1: Six cases of PID control strategies.
Case Description
1 two linear PID controllers
2 two T1 fuzzy PID controllers
3 two IT2 fuzzy PID controllers
4 one linear PID controller with scaling factors
5
one T1 fuzzy PID controller with T1
fuzzy scaling factors
6
one IT2 fuzzy PID controller with IT2
fuzzy scaling factors
In each of these two groups, we have the following control strategies: lin-
ear PID controllers, T1 fuzzy PID controllers, and IT2 fuzzy PID controllers.
For fuzzy PID controllers, the block diagram of BIS index regulation using two
controllers and one controller with scaling factors are shown in Figure 4.6 and
Figure 4.7, respectively. Referring to the figures, r(t) denotes the desired BIS
target value, y(tk) is the output BIS value from the anaesthesia model, e(tk) de-
notes the difference between the desired target and actual BIS value at time tk,
i.e. e(tk) = r(tk)− y(tk). The PID gains (KP1 , KI1 , KD1 , KP2 , KI2 and KD2) and
scaling factors (αr and αp) are decided by the fuzzy inference systems. The PID
controller will generate the control signals up(tk) and ur(tk) for BIS regulation
where up(tk) and ur(tk) are Cptprop and Cptremi in Figure 4.1.
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Figure 4.7: BIS index regulation using one fuzzy PID controller with scaling
factors.
4.4.3 Fuzzy Rules
T1 and IT2 fuzzy PID controllers are discussed in subsections 4.3.2 and 4.3.3,
respectively. While the number of fuzzy rules and the shape of membership func-
tion are predefined, the parameters of input and output membership functions
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are optimized by GA.
In this chapter, the shape of membership functions is defined as a triangu-
lar shape for simplicity. The triangular IT2 membership functions are shown
in Figure 4.8. For each input IT2 membership functions, the lower and upper
membership functions are characterized by seven points p1 to p7 which are to be
optimized by GA. As for the T1 fuzzy PID controller, each input membership
function is characterized by three points p1 to p3 which are to be optimized by
GA. For both the T1 and IT2 fuzzy PID controllers, their output membership












Figure 4.8: An example of IT2 membership functions. Dashed line: lower mem-
bership function. Dotted line: Upper membership function. Grey area: footprint
of uncertainty.
In fact, from the determination of membership functions and fuzzy rules, we
can find the relation between these control strategies: solutions for linear PID
controllers can be implemented by T1 fuzzy PID controllers, and solutions for
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T1 fuzzy PID controllers can be implemented by IT2 fuzzy PID controllers. In
other words, linear PID controller is a subset of T1 fuzzy PID controller, and T1
fuzzy PID controller is a subset of IT2 fuzzy PID controller. By adding some
constraints on the membership functions and consequents in fuzzy rules, IT2
fuzzy PID controllers can be reduced to T1 fuzzy PID controllers, and T1 fuzzy
PID controllers can be reduced to linear PID controllers.
Three rules are employed for each fuzzy inference system. The premise of
each rule takes only one linguistic variable, i.e., ∆BIS(tk) = BISt(tk) − BIS(tk)
where BISt(tk) is the target BIS value at time tk and BIS(tk) is the actual BIS
value. Three linguistic terms, namely negative (N), zero (Z), and positive (P ),
are employed to characterize the premise variable ∆BIS(tk). More rules can be
used to partition the universe of discourse for a better result. However, it will lead
to slower convergence of training and more computational burden. Additionally,
the rate of change of ∆BIS(tk) can also be treated as another linguistic variable
together with ∆BIS(tk). Likewise, it will cause more fuzzy rules and parameters
which increases the computational burden and defers the convergence.
From the above discussion, triangular membership functions and three rules
are employed for both T1 and IT2 fuzzy PID controllers. In the GA optimization,
the triangular shape and sequence of membership functions of three rules should
be guaranteed. For the sequence, specifically, the same point in membership
functions corresponding to linguistic terms N , Z and P should be in ascending
order (except p7). For example, Np2 < Zp2 < Pp2, where Np2, Zp2, and Pp2 are
points p2 for membership functions corresponding to linguistic terms N , Z and
P , respectively.
Another condition which needs to be ensured is that at least one rule is fired
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for ∆BIS(tk) ∈ [−100, 100]. Between two adjacent membership functions, as long
as they intersect with each other, there exists one rule to be fired. On the left-
hand side of membership function N and the right right-hand side of membership
function P , there are two approaches to ensure this condition. One is defining
Np2 = −100 and Pp2 = 100, and another is defining Np1 = Np4 = −∞ and
Pp3 = Pp6 = +∞. It can be found that solutions from the first approach can
be implemented by the second approach. In other words, the second approach is
more general than the first approach. Hence, the second method is adopted. For
that reason, N and P are two shoulder-shape membership functions which can be
treated as a special case of triangular membership functions. In this approach, it is
guaranteed that at least one rule is fired for ∆BIS(tk) ∈ (−∞,+∞), although only
[−100, 100] is concerned practically. Note that under this method the equalities
Np1 = Np4 = Np2 and Pp3 = Pp6 = Pp2 are temporarily employed in the
optimization.
4.4.4 Parameters Optimization
The PID gains, scaling factors and membership functions are optimized by GA
subject to a cost function reflecting the control performance. Due to the disparity
of each training, GA is run 10 times for each case of PID control strategy as
shown in Table 4.1. The best set of parameters for each control strategy for each
run of GA is recorded for further comparison, analysis and practical application.
Statistical information including the worst, mean and best costs and the standard
deviation for the 10 runs are collected. Among the 10 runs for each PID control
strategy, the best set of parameters given by the best cost is used to implement
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the corresponding PID controller. During the optimization, the lower and upper
bounds (LB and UB) of PID gains and scaling factors are listed in Table 4.2,
which are determined by trial and error for good control performance.
Table 4.2: Lower and upper bounds of parameters
KP1 , KP2 KI1 , KI2 KD1 , KD2
LB UB LB UB LB UB
−10 0 −0.1 0 −10 0
αp αr
LB UB LB UB
0 1 0 1
Due to a large number of variables and the highly nonlinear cost function
(defined in the following subsection 4.4.5), especially for fuzzy PID controllers,
GA may not be able to reach the global optimal solution. To speed up the train-
ing process, the initial population for fuzzy PID controllers is defined based on
knowledge of the PID control strategy. It is known that the linear PID controller
is a subset of T1 fuzzy PID controller, and the T1 fuzzy PID controller is a subset
of IT2 fuzzy PID controller. It is thus reasonable that the best set of PID gains
for linear PID controllers obtained by GA is employed as the initial PID gains
for T1 fuzzy PID controllers for all rules. As a result, initially, the T1 fuzzy
controller is equivalent to a linear PID controller. Similarly, the best set of PID
gains and membership function parameters obtained for T1 fuzzy PID controller
is employed as the initial set of PID gains and membership function parameters
for IT2 fuzzy PID controller. That is to say, the “knowledge” of the PID control
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strategy is utilized such that GA starts with a considerably good initial condition.
In this way, although there is still the same number of variables to be trained, GA
only needs to utilize the additional parameters and new structures (fuzzy rules
and membership functions) provided by fuzzy PID controllers in order to obtain
a better cost value.
4.4.5 Performance Index
The performance index is used to judge whether the control objective is achieved
and show the merits of various control strategies. Different performance indices
can be selected such as settling time, overshoot, steady error, mean absolute
error (MAE), and mean square error (MSE). For the GA optimization, a well-
defined performance index is required as the cost function. All parameters of the
controllers are optimized by minimizing the cost function. In this chapter, the






















where tk = kT, k = 0, 1, 2, . . . , n, is the sampling time, and n is a positive in-
teger; T is the sampling period; ∆BIS(tk) = BISt(tk) − BIS(tk), BISt(tk) is the
target BIS value at time tk, and ∆BIS(t−1) = 0; Cptprop(tk) and Cptremi(tk)
are plasma concentration targets of propofol and remifentanil, respectively, and
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Cptprop(t−1) = Cptprop(t0), Cptremi(t−1) = Cptremi(t0); λ1, λ2, . . . , λ5 are prede-
fined weights.
In the cost function equation (4.17), the first term is MAE which aims at mini-
mizing the difference between the current BIS value and its target. Unlike settling
time, overshoot and steady error, MAE and MSE record the error information
through all simulation periods which reflect more comprehensive properties of
performance. The reason to choose MAE instead of MSE is that MSE amplifies
the effect of large errors and then the optimization tries to minimize large errors
which results in oscillation. On the other hand, MAE keeps the original weights
on large and small errors leading to a mild and smooth response.
The three terms after the first term of equation (4.17) are the rate of change
of ∆BIS(tk), Cptprop(tk) and Cptremi(tk), respectively, which are designed to give
a smooth response. The last term is to reduce the difference of the concentration
of two drugs because they are equally important for different purposes during the
anaesthesia. Serious differences in either of these two drugs will not provide an
adequate anaesthesia.
4.5 Simulation Results
In this section, the simulation of the control of anaesthesia using the anaesthesia
model in Figure 4.1 is implemented. Different control strategies in Table 4.1 are
applied to regulate the BIS using the training profiles shown in Figure 4.4 for
training and their control performance are verified by testing profiles shown in
Figure 4.5. PID gains, parameters of scaling factors and membership functions
are optimized by GA according to the cost function (4.17). Comparisons of per-
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formance are made between the six cases. It should be noted that the simulation
was carried out in discrete time. The PK model in equation (4.1) was discretized
using the zero-order-hold (ZOH) assumption.
A real-coded GA available from Matlab global optimization toolbox is em-
ployed for the training. The control parameters of GA are listed in Table 4.3.
Table 4.3: Control parameters of GA.
Parameter Value
Number of iterations 200
Size of population 100
Selection Stochastic uniform selection func-
tion
Elitism Elitism is implemented. The best
two chromosomes are guaranteed




Stopping criterion It stops if the weighted average
relative change in the best fitness
function value over 100 genera-
tions is less than or equal to 10−6.
The parameters in equation (4.17) are defined as follows: n = 1000, T = 10
seconds, λ1 = λ5 = 1, λ2 = λ3 = λ4 = 20. It is worth mentioning that although
the weight λ1 is not the largest, the MAE is still the main contribution to the
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total cost. The bounds of parameters in Table 4.2 are adopted for the training
process of GA. By running GA 10 times for each case in Table 4.1, it obtains the
statistical information of the cost J as shown in Table 4.4.
Table 4.4: The cost J from running GA 10 times
Case Description Best Worst Std Mean
1 2 linear PID 4.0546 6.0544 0.6915 4.7190
2 2 T1 PID 3.8913 4.0479 0.0439 3.9273
3 2 IT2 3.8606 3.8899 0.0091 3.8825
4 1 linear PID with s.f. 4.0585 4.0594 0.0003 4.0587
5 1 T1 PID with T1 fuzzy with s.f. 3.9544 3.9780 0.0073 3.9696
6 1 IT2 PID with IT2 fuzzy with s.f. 3.9264 3.9437 0.0060 3.9380
Referring to Table 4.4, comparing with Cases 1 to 3, Case 3 offers the best cost
and Case 2 comes second which comples with the theory. The same rank can be
found in Cases 4 to 6. Comparing Cases 1 and 4, two-controller case is better than
one-controller case, which can be also proved by comparing Cases 2 and 5, and
Cases 3 and 6. The reason is that one-controller case has the constraint on the
ratio of control signals between two drugs while two-controller case does not have
such constraint. One-controller case is a subset of two-controller case. Although
one-controller case performs worse, it has fewer parameters to be determined and
thus reduces the computational demand and implementation cost of PID control
strategy.
In spite of the “Best” cost, the “Std” (standard deviation) is descending from
linear PID controllers to IT2 fuzzy PID controller except in Case 4. It provides
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the information that the convergence gets easier for fuzzy PID controllers. The
reason is that we use the best set of parameters in previous cases as the initial
populations in subsequent training. It also indicates that the improvement be-
comes more and more difficult, and thus 10 times running offers similar results.
The “Std” for two-controller cases is larger than the corresponding one-controller
cases, which implies that the convergence for two-controller cases is harder due
to more variables to be trained.
The best sets of parameters and membership functions are shown in Table 4.5
to Table 4.14. Corresponding membership functions are exhibited in Figure 4.9
to Figure 4.12. From the obtained membership functions, it can be summarized
that points |Np2| and |Pp2| are preferred to be around 20 related to the training
profiles we define in Figure 4.4. Considering that the only linguistic variable is
∆BIS(tk) and the maximum change of BISt(tk) is ±30 in the training profile, it is
reasonable to choose ∆BIS(tk) ∈ [−30, 30] as an estimated domain where the PID
controllers work suggests that the fuzzy blending should start from around ±20.
For the IT2 membership functions of IT2 fuzzy PID controllers in Figure 4.10
and Figure 4.12 after training, it was found that the lower and upper membership
functions are very close to each other such as membership functions of N and Z in
Figure 4.10. The values of points (p1 to p7) associated with the IT2 membership
functions are shown in Tables 4.9 and 4.14.
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Table 4.6: Best set of parameters for two T1 fuzzy PID controllers
Rule KP1 KI1 KD1
N −0.0531 −0.0002 −0.5027
Z −1.8031 −0.0004 −4.0368
P −2.5531 −0.0004 −0.0028
KP2 KI2 KD2
N −0.2203 −0.0012 −0.0910
Z −0.2203 −0.0012 −1.5909
P −7.5162 −0.0012 −0.5910
Table 4.7: Best set of membership functions for two T1 fuzzy PID controllers
Rule p1 p2 p3
N −∞ −19.0370 7.0855
Z −7.1950 5.7480 13.1011
P −1.1593 19.0370 +∞
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Figure 4.9: Membership functions for two T1 fuzzy PID controllers. Dashed
line: membership function N . Dotted line: membership function Z. Solid line:
membership function P .
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Table 4.9: Best set of membership functions for two IT2 fuzzy PID controllers
Rule p1 p2 p3 p4
N −∞ −19.0371 7.0975 −∞
Z −7.2069 5.7480 13.4781 −7.1951
P −1.4565 19.0371 +∞ −1.1593
p5 p6 p7
N −19.0371 7.0856 0.9990
Z 5.7480 13.1011 0.9990
P 19.0371 +∞ 0.8135





Figure 4.10: Membership functions for two IT2 fuzzy PID controllers. Dashed
line: lower membership functions. Dotted line: upper membership functions.
Solid line: the shoulder of membership functions.
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Table 4.10: Best set of parameters for one PID controller
KP1 KI1 KD1 αp αr
−0.9267 −0.0061 −0.6068 0.0598 0.1869
Table 4.11: Best set of parameters for one T1 fuzzy PID controller with T1 fuzzy
scaling factors
Rule KP1 KI1 KD1 αp αr
N −0.8642 −0.0061 −0.5443 0.0665 0.2189
Z −1.7068 −0.0054 −9.6913 0.0725 0.1869
P −8.6575 −0.0061 −6.6119 0.0602 0.1947
Table 4.12: Best set of membership functions for one T1 fuzzy PID controller
with T1 fuzzy scaling factors
Rule p1 p2 p3
N −∞ −24.6107 −10.1748
Z −11.4184 −6.9156 1.8562
P −9.1078 24.6107 +∞
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Figure 4.11: Membership functions for one T1 fuzzy PID controller with T1 fuzzy
scaling factors. Dashed line: membership function N . Dotted line: membership
function Z. Solid line: membership function P .
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N [−0.5443,−0.5273] [0.0665, 0.0742]
Z [−9.6913,−9.6393] [0.1037, 0.1248]






4. CONTROL OF ANAESTHESIA USING PK AND PD MODELS
Table 4.14: Best set of membership functions for one IT2 fuzzy PID controller
with IT2 fuzzy scaling factors
Rule p1 p2 p3 p4
N −∞ −24.6105 −5.0849 −∞
Z −13.6412 −6.9156 2.2345 −13.6302
P −9.1233 24.6105 +∞ −9.1078
p5 p6 p7
N −24.6105 −7.0984 0.9990
Z −6.9156 1.8562 0.9990
P 24.6105 +∞ 0.9990







Figure 4.12: Membership functions for one IT2 fuzzy PID controllers with IT2
fuzzy scaling factors. Dashed line: lower membership functions. Dotted line:
upper membership functions. Solid line: the shoulder of membership functions.
By applying the best sets of parameters to the training profile of BIS, the time
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responses of BIS and corresponding drug concentration information are shown
in Figure 4.13 to Figure 4.18 for Cases 1 to 6, respectively. By applying the
best sets of parameters to the testing profile of BIS, the ones for the testing
profile are exhibited in Figure 4.19 to Figure 4.24. The green line is drawn by
BIS(tk) = BISt(tk)± 2. Despite BIS value during general anaesthesia is aimed to
be with the 40 to 60 band, from the practical clinical point of view, the acceptable
range of BIS is [BISt(tk)− 5,BISt(tk) + 5]. Therefore, if BIS is stabilized within
the region bounded by the lower and upper green lines, the performance will be
more than acceptable.































Figure 4.13: BIS and drug concentration for training profile by two PID con-
trollers.
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Figure 4.14: BIS and drug concentration for training profile by two T1 fuzzy PID
controllers.































Figure 4.15: BIS and drug concentration for training profile by two IT2 fuzzy
PID controllers.
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Figure 4.16: BIS and drug concentration for training profile by one PID controller
with scaling factors.































Figure 4.17: BIS and drug concentration for training profile by one T1 fuzzy PID
controller with T1 fuzzy scaling factors.
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Figure 4.18: BIS and drug concentration for training profile by one IT2 fuzzy
PID controller with IT2 fuzzy scaling factors.































Figure 4.19: BIS and drug concentration for testing profile by two PID controllers.
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Figure 4.20: BIS and drug concentration for testing profile by two T1 fuzzy PID
controllers.































Figure 4.21: BIS and drug concentration for testing profile by two IT2 fuzzy PID
controllers.
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Figure 4.22: BIS and drug concentration for testing profile by one PID controller
with scaling factors.































Figure 4.23: BIS and drug concentration for testing profile by one T1 fuzzy PID
controller with T1 fuzzy scaling factors.
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Figure 4.24: BIS and drug concentration for testing profile by one IT2 fuzzy PID
controller with IT2 fuzzy scaling factors.
The figures show that all cases of PID control strategies succeed in tracking
the BIS targets and maintaining BIS values. In terms of control performance,
while the linear PID controllers have less steady error, fuzzy PID controllers have
less overshoot and settling time. Since there is no rigorous requirement on small
steady error, fuzzy PID controllers are preferable in that they are able to keep the
BIS values within the regions bounded by the green lines with less overshoot and
settling time. Both training and testing profiles demonstrate the same character-
istics as discussed for the corresponding control strategies. Recalling a common
controller with two linear PID controllers and predefined parameters is used to
achieve the induction process for all cases, the proposed PID control strategies
kick in at the start of the maintenance process. The switching point in the in-
duction and maintenance process occurs at 1000 seconds which results in a small
vibration.
126
4. CONTROL OF ANAESTHESIA USING PK AND PD MODELS
The lower panels of Figure 4.19 to Figure 4.24 show the behavior of drug
concentration. It can be seen that both Cp and Ce of propofol and remifentanil
are adjusted by controllers according to target profiles. More importantly, they
are adjusted in advance to decrease the overshoot. This is mainly because all
controllers are based on PID control strategy, whose abilities are inherited. In
addition, the total amount of remifentanil is larger than propofol, which illus-
trates that the remifentanil is more favorable to the stabilization of BIS than the
propofol. This might be due to the faster acting time of remifentail compara-
tively to propofol. Although the total amount of remifentanil is larger, the cost
function takes the difference of the amount of two drugs into consideration such
that serious bias to remifentanil is avoided. Even though the slight bias towards
remifentanil can be noticed overall the propofol and remifentanil Ce reached are
within acceptable clinical boundaries even when the BIS target was set at 20, a
value inferior to the safe interval of 40 to 60.
Overall, from a clinical point of view the results and performance obtained
are acceptable, considering the lack of significant overshoot, the stability of the
controller response and the ability to achieve the desired targets in a short time
with clinically acceptable Ce. The controller also provided the expected response
when the value of BIS target increased, and it stops the infusion of anaesthetic
drugs and only restarts its infusion to avoid an overshot.
When the PID control strategies with the best set of parameters (offering the
best cost of J) are employed to regulate the BIS value using the testing profile
in Figure 4.5, their cost values are listed in Table 4.15. The rank of which is
identical to the sequence of cost values from the training profile. It indicates that
the advantage of fuzzy PID controller over linear PID controller exists not only
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in the training profile, but also in various target profiles.
Table 4.15: The cost J for the testing profile
Case 1 2 3
Cost 4.1175 3.9888 3.9745
Case 4 5 6
Cost 4.1228 4.0408 4.0166
4.6 Summary
In this chapter, drug administration for anaesthesia has been realized by various
PID control strategies. From the multivariable anaesthesia model with propofol
and remifentanil based on 42 patients’ clinical data constructed on Chapter 3,
simulations have been conducted to regulate the output BIS value governed by
this model using six control strategies including linear PID controllers, T1 fuzzy
PID controllers and IT2 fuzzy PID controllers. These six strategies are separated
into two groups, namely two controllers and one controller with scaling factors,
to handle the co-administration of two drugs. Parameters of these controllers
have all been optimized by GA subject to a performance index quantitatively
measuring the control performance. In order to make the control sophisticated,
target profiles have been designed for BIS regulation. Different target profiles
have been utilized to test and verify the performance of controllers.
It has been demonstrated that the IT2 fuzzy PID controllers offer the best
performance, and that the T1 fuzzy PID controllers come second.
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Chapter 5
Conclusions and Future work
5.1 Conclusions
In this thesis PK/PD modelling able to describe the effect of anaesthetic drugs
and automatic control of general anaesthesia was studied. A PK/PD model de-
scribing propofol and remifentanil interactions and their real clinical effect mea-
sured as BIS index were obtained through Hill and SVR-based techniques from
clinical data obtained at King’s College Hospital. Automatic control design for
general anaesthesia was also proposed and tested based on the Hill-based PK/PD
model obtained.
In order to achieve these a clinical platform for data recording was assembled
in the operating theatre. This platform enabled the recording of a variety of
clinical signals for a significant number of surgeries throughout the duration of
this research project. The recorded data was analyzed and parameters of Hill’s
PD model were estimated by GA using different cost functions and least squares
curve fitting method. Additional research performed with the aim of obtaining a
more accurate PD model using SVR techniques with the consideration of different
kernel functions and different model structure including additional information
129
5. CONCLUSIONS AND FUTURE WORK
such as nCO. As the SVR-based PD model is a non-parametric model an evalua-
tion function to measure the modelling performance and validity of the developed
SVR-based PD model was developed. SVR-based PD models have shown good
performance results and adequacy depending on the kernel function.
A realistic PK/PD model is a requirement for developing automatic/advisor
control structures for anaesthetic drugs, since all work has to be done in simula-
tion, before it can be tested in animal or human patients. Therefore, the SVR
model structure shows a great potential for practical implementation, both as
simulation (learning) tool for clinicians and also as a basis for the development of
an advisor control system for drug infusion for general anaesthesia under surgery.
One of the applications of these models is a simulation structure (incorpo-
rating alarms) that can help to train clinicians in the PK/PD changes and the
effect of intravenous drugs. Disturbances can be used to simulate adverse and
unexpected events (or just unstable situations), and in this way predict the effect
of haemodynamic changes as well as concentration changes on the patients brain
response.
The traditional PID controller, type-1 fuzzy PID controller and interval type-2
fuzzy PID controller were studied in this thesis. These control methodologies were
designed and tested based on the PK/PD model within the patient’s parameters.
A fitness function to measure the regulation performance of BIS index value was
generated allowing the use of GA to determine the controller gains by optimizing
it.
The PK/PD model was generated from real clinical data based upon a typical
PD modelling approach and a proposed SVR-based technique allowing incorpora-
tion of additional information. These are employed to describe the dynamics of a
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patient’s body responding to the anaesthetic drugs, propofol and remifentanil. A
closed-loop system for drug administration such that BIS index can be controlled
formed by the PK/PD model and a controller was evaluated.
5.2 Future work
As all the clinical data used in the project has been collected from one operating
theatre with one anaesthesiologist, the type of surgeries and group of patient
tends to be quite homogeneous. Having additional clinical data is an objective
that should be followed in the future to improve PD models. All the data has
been recorded as part of usual anaesthetic practice, however for the benefit of PD
modelling, a clinical dataset incorporating unusual concentrations of anaesthetic
and its effect would be of great value.
Even through it is not possible to perform online measurements of accurate
anaesthetic drugs concentrations, all the PD modelling has been performed under
estimated concentration, therefore obtaining actual drugs concentrations would
be valuable.
In the future, further investigations can be carried out to control a general
and non-parametric multivariable anaesthesia model rather than the model with
parameters obtained from a specific group of patients.
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Figure 1: Implemented pharmacokinetic model.
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Figure 2: First compartment.
Figure 3: Second compartment.
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Figure 4: Third compartment.
Figure 5: Effect-site compartment.
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